<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12475083</article-id><article-id pub-id-type="pmcid-ver">PMC12475083.1</article-id><article-id pub-id-type="pmcaid">12475083</article-id><article-id pub-id-type="pmcaiid">12475083</article-id><article-id pub-id-type="pmid">41006293</article-id><article-id pub-id-type="doi">10.1038/s41598-025-02774-6</article-id><article-id pub-id-type="publisher-id">2774</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Novel selective indole based histone deacetylase 10 inhibitors as anticancer therapeutics</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tarawneh</surname><given-names initials="AH">Amer H.</given-names></name><address><email>amer.tarawneh@ttu.edu.jo</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Al-Trawneh</surname><given-names initials="SA">Salah A.</given-names></name><address><email>laratr@mutah.edu.jo</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yesiloglu</surname><given-names initials="TZ">Talha Z.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zessin</surname><given-names initials="M">Matthes</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Robaa</surname><given-names initials="D">Dina</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barinka</surname><given-names initials="C">Cyril</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schutkowski</surname><given-names initials="M">Mike</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Sippl</surname><given-names initials="W">Wolfgang</given-names></name><address><email>wolfgang.sippl@pharmazie.uni-halle.de</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ross</surname><given-names initials="SA">Samir A.</given-names></name><address><email>sross@olemiss.edu</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04jzmk773</institution-id><institution-id institution-id-type="GRID">grid.449604.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0421 7127</institution-id><institution>Department of Chemistry, Faculty of Science, </institution><institution>Tafila Technical University, </institution></institution-wrap>P.O. Box 179, Tafila, 66110 Jordan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/008g9ns82</institution-id><institution-id institution-id-type="GRID">grid.440897.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0686 6540</institution-id><institution>Chemistry Department, Faculty of Science, </institution><institution>Mu&#8217;tah University, </institution></institution-wrap>Karak, 61710 Jordan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02teq1165</institution-id><institution-id institution-id-type="GRID">grid.251313.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2169 2489</institution-id><institution>National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, </institution><institution>University of Mississippi, </institution></institution-wrap>University, MS 38677 USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gqaka33</institution-id><institution-id institution-id-type="GRID">grid.9018.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0679 2801</institution-id><institution>Institute of Pharmacy, </institution><institution>Martin-Luther University of Halle-Wittenberg, </institution></institution-wrap>06120 Halle/Saale, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gqaka33</institution-id><institution-id institution-id-type="GRID">grid.9018.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0679 2801</institution-id><institution>Institute of Biotechnology, </institution><institution>Martin-Luther University of Halle-Wittenberg, </institution></institution-wrap>06120 Halle/Saale, Germany </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wzqmx94</institution-id><institution-id institution-id-type="GRID">grid.448014.d</institution-id><institution>Institute of Biotechnology of the Czech Academy of Sciences, </institution><institution>BIOCEV, </institution></institution-wrap>Prumyslova 595, 252 50 Vestec, Czech Republic </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02teq1165</institution-id><institution-id institution-id-type="GRID">grid.251313.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2169 2489</institution-id><institution>Department of BioMolecular Sciences, School of Pharmacy, </institution><institution>University of Mississippi, </institution></institution-wrap>University, MS 38677 USA </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>33307</elocation-id><history><date date-type="received"><day>3</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 16:25:18.507"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_2774.pdf"/><abstract id="Abs1"><p id="Par1">Histone deacetylase (HDAC) inhibitors represent a promising class of anti-cancer agents that play a key role in both epigenetic and non-epigenetic regulation, leading to cancer cell death, apoptosis, and cell cycle arrest. This study synthesized novel bicyclic hydroxamic acid derivatives and evaluated their inhibitory and selectivity activity against class I and IIb HDACs. Our findings demonstrate that Compound <bold>2e</bold> specifically inhibits HDAC10 with high selectivity over HDAC6, while shows no significant impact on class I HDACs. Compound <bold>2a</bold> exhibited the most potant inhibitory activity against HDAC10, with IC<sub>50</sub> 0.41&#8201;&#177;&#8201;0.02 nM. In contrast, Compound <bold>2f</bold> revealed a preference toward HDAC6, with an IC<sub>50</sub> value of 2.5&#8201;&#177;&#8201;0.3 nM. Compounds <bold>2c</bold> and <bold>2d</bold> demonstrated high selectivity toward class IIb over class I HDACs. Docking and molecular dynamics studies revealed that compound <bold>2a</bold> fits well into the active site of HDAC10, forming stable and strong interactions with key residues F204, D94, W205, and E274 in HDAC10. In addition, we assessed the anti-proliferative activity these compounds against a panel of four human solid tumor cell lines. To evaluate their selectivity, non-cancerous kidney cell lines (LLC-PK1 and VERO) were employed to determine the effects of these compounds on normal cell proliferation.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-02774-6.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Histone deacetylases</kwd><kwd>HDAC10 inhibitors</kwd><kwd>Tumor cell lines</kwd><kwd>Molecular docking</kwd><kwd>Molecular dynamics</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Chemistry</kwd><kwd>Medicinal chemistry</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par3">Histones play a crucial role in regulating gene expression, the process by which the coded information in genes is converted into functional structures within the cell. Histone acetylation (HA) neutralizes the positive charge on histones by converting amine groups into amide groups<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. This modification reduces the affinity of histone for DNA, leading to chromatin relaxation (chromatin expansion), which permotes genetic transcription<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>. Histone deacetylases (HDACs) are enzymes that remove the acetyl group from acetylated lysine residues on both histone and non-histone proteins. This removal restores the positive charge on histones, increasing their affinity for DNA and resulting in chromatin condensation, which suppresses gene expression. Histones are basic proteins present in the chromatin of eukaryotic cell nuclei and are essential for organizing DNA into structural units called nucleosomes, the fundamental repeating units of chromatin<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par4">There are 18 subtypes of HDACs encoded in the human genome. These enzymes are categorized into two main groups; the first group comprisesis zinc-dependent HDACs, which are further divided into the following sub-classes: class Ia (HDAC1, HDAC2), class Ib (HDAC3), and class Ic (HDAC8), class IIa (HDAC4, HDAC5, HDAC7, and HDAC9), class IIb (HDAC6 and HDAC10), and class IV (HDAC11). The second group consists of nicotinamide adenine dinucleotide (NAD<sup>+</sup>)-dependent HDACs, known as class III HDACs or sirtuins<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>. Accumulating evidence has domonstrated the crucial role of HDACs in various cellular processes, including autophagy, cell cycle control, and apoptosis<sup><xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref></sup>. Recent studies indicate the protective role of HDACs function against DNA damage, making them promising anti-tumor therapies<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p><p id="Par5">Several HDAC inhibitors have been identified, and some (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>) were approved by FDA. For instance, <bold>vorinostat</bold> (SAHA) was approved for the treatment of cutaneous T cell lymphoma (CTCL)<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, Recently, the introduction of an amino group (&#8220;aza-scan&#8221;) into the hexyl linker moiety of vorinostat (SAHA) yielded a selective chemical probe, DKFZ-748, targeting histone deacetylase 10 (HDAC10). This modification conferred unprecedented selectivity for HDAC10 over other HDAC isozymes, highlighting its potential as a highly specific therapeutic tool<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. While <bold>belinostat</bold> (PXD-101) and <bold>romidepsin</bold> (FK-228) were approved for the treatment of peripheral T-cell lymphoma (PTCL)<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. Romidepsin has also shown efficacy in treating bipolar disorders and migraine. In addition, <bold>panobinostat</bold> (LBH-589) was approved for the treatment of multiple myeloma. These inhibitors induce growth arrest, differentiation, and apoptosis of many transformed cells, thereby eliminating cancer cells<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. The catalytic domains of zinc-dependent HDACs share a high degree of homology. However, the lack of isoform specific selectivity in approved HDAC inhibitors often leads to potential side effects<sup><xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref></sup>. Non-selective HDAC inhibitors, such as vorinostat and panobinostat modulate multiple pathways and factors in MDA-MB-231, 4T1, and BT-549 cell lines. this effect includes the suppression of growth factor FOXA1<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, upregulation of tumor suppressor factors p21 and p27, and downregulation of the anti-apoptotic protein Bcl-2<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. In addition, both inhibitors can suppqress matrix metalloproteinase (MMP9) activity<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>.</p><p>
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Example of approved HDAC inhibitors by the Food and Drug Administration (FDA).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e408" position="float" orientation="portrait" xlink:href="41598_2025_2774_Fig1_HTML.jpg"/></fig>
</p><p id="Par8">Recently, HDAC10 has been shown to play a unique role in neuroblastoma cells, where its inhibition lead to the accumulation of autolysosomes. This result indicates that HDAC10 may be potential therapeutic target for neuroblastoma treatment<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Conversely, HDAC10 has been found to suppress tumorigenesis in cervical cancer by downregulating miR-233 expression, which subsequently targeting EPB41L3<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Consequently, there is a critical need for HDAC10-selective chemical probes to validate its role in both physiological and pathological processes. Such tools are essential to establish a mechanistic connection between HDAC10&#8217;s function as a polyamine deacetylase and the phenotypic outcomes observed following genetic manipulation of HDAC10. Additionally, HDAC10 inhibitors (HDAC10i) hold substantial therapeutic promise, particularly in oncology and as immunomodulatory agents<sup><xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref></sup>.</p><p id="Par9">Investigating the biological relevance of HDAC10 and evaluating its pharmacological role in cancer cell lines highlight the need for selective HDAC10 inhibitors. To date, only few inhibitors targeting HDAC10 have been identified<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, such as tubastatin A and its derivative (1b), which are selective for HDAC subfamily IIb<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Recently, TH34 was reported as a class I/IIb selective HDAC inhibitor<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Additionally, compounds including 2-(oxazol-2-yl)phenol moiety have been identified as HDAC1/6/10 inhibitors<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. The importance of a basic moiety in the linker group has also been demonstrated in a recently developed series of piperidine-based HDAC10 inhibitors<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. A major challenge lies in introducing HDAC10 inhibitors with high selectivity over the class IIb isozyme member HDAC6.</p><p id="Par10">Most HDAC inhibitors exhibit a conserved pharmacophoric features, including a &#8216;cap&#8217; group and hydrophobic chain (linker); both of which influence selectivity. Additionally, the zinc-binding group (ZBG) is critical for the inhibitor&#8217;s potency<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. SAHA<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, a pan-HDAC inhibitor, holds the distinction of being the first HDAC inhibitor approved for clinical use (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Its structure features a hexyl linker (black), which serves as a mimic of the lysine side chain. This linker connects the hydroxamic acid zinc-binding group (red) to the anilide &#8220;cap&#8221; group (green), forming the core architecture of the molecule. We hypothesized that mimicking the structural framework of SAHA<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> and Panobinostat (LBH-589)<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> inhibitors by incorporating hydrophobic moieties, such as indole or quinoline&#8212;privileged structures commonly found in various anticancer drugs. Additionally, the inclusion of an amino group and a hydroxamic acid would introduce high polarity, while the use of indole or quinoline as cap groups could improve their drug-like properties. On the other hand, to optimize physicochemical properties and minimize the number of rotatable bonds, we proposed the use of rigid linkers, such as piperidine and aromatic moeity. The significance of incorporating a basic moiety within the linker group has been further supported by recently developed series of HDAC10 inhibitors<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. Herein, we report efforts to optimize indole and quinoline ligands as HDAC10-selective inhibitors. Several modified derivatives that were developed exhibited significant HDAC10 inhibition and selectivity.</p></sec><sec id="Sec2"><title>Results and discussion</title><sec id="Sec3"><title>Chemistry</title><p>The compounds in this study were synthesized as outlined in Schemes <xref rid="Sch1" ref-type="fig">1</xref> and <xref rid="Sch2" ref-type="fig">2</xref>. The starting building block, 1H-indole-3-carbaldehyde, was treated with 4-methylbenzene-1-sulfonyl chloride in anhydrous <italic toggle="yes">N</italic>, <italic toggle="yes">N</italic>&#8217;-Dimethylformamide (DMF) using sodium hydride as a base, this intermediate was then coupled with various amine compounds via a reductive amination reaction using sodium triacetoxyborohydride ((CH<sub>3</sub>COO)<sub>3</sub>BHNa). Finally, a condensation reaction with hydroxylamine and potassium hydroxide KOH to afford final targeted compounds 2c-e, as shown in Scheme <xref rid="Sch1" ref-type="fig">1</xref>.</p><p>
<fig id="Sch1" position="float" orientation="portrait"><label>Scheme 1</label><caption><p>Reagent and condition: (<bold>a</bold>) DMF, NaH, TsCl, ice bath, 15&#160;min. (<bold>b</bold>) CH<sub>2</sub>Cl<sub>2</sub>, (CH<sub>3</sub>COO)<sub>3</sub>BHNa, <italic toggle="yes">r</italic>.t, overnight. (<bold>c</bold>) CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:2), hydroxylamine (50 wt % in H<sub>2</sub>O), NaOH, <italic toggle="yes">r</italic>.t, 24&#160;h.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e547" position="float" orientation="portrait" xlink:href="41598_2025_2774_Sch1_HTML.jpg"/></fig>
</p><p>
<fig id="Sch2" position="float" orientation="portrait"><label>Scheme 2</label><caption><p>Reagent and condition: (<bold>a</bold>) CH<sub>2</sub>Cl<sub>2</sub>, (CH<sub>3</sub>COO)<sub>3</sub>BHNa, r.t, overnight. (<bold>b</bold>) CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:2), hydroxylamine (50 wt % in H2O), NaOH, r.t, 24&#160;h.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e577" position="float" orientation="portrait" xlink:href="41598_2025_2774_Sch2_HTML.jpg"/></fig>
</p><p>Similarly, indole-3-carboxaldehyde and quinolone were treated in the same manner as indole-3-carboxaldehyde to produce compounds <bold>2a-b</bold>, and <bold>2f</bold>-<bold>g</bold> Schemes <xref rid="Sch1" ref-type="fig">1</xref> and <xref rid="Sch2" ref-type="fig">2</xref>.</p></sec><sec id="Sec4"><title>Pharmacology/biology</title><sec id="Sec5"><title>Synthesis and in vitro testing of novel inhibitors</title><p id="Par12">Recently, piperidine-4-acryl hydroxamates (<bold>PZ45</bold> and <bold>PZ48</bold>) were reported as potent HDAC10 inhibitors with high specificity for HDAC10 over HDAC6 and with no significant impact on class I HDACs<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. The selectivity of these newly discovered ligands <bold>PZ45/48</bold> was further evaluated in acute myeloid leukemia (AML) cells harboring the FLT3-ITD oncogene, demonstrating promising activity.</p><p id="Par13">In the current work, we extended the structure-activity relationships of HDAC10 inhibitors by synthesizing a series of benzhyldroxamic acid derivatives featuring a zinc-binding group (ZBG) and a bicyclic aromatic moiety as a capping group. These derivatives were designed with a methylene spacer linked to a basic amine group, maintaining the common pharmacophoric features essential for HDAC inhibition as previously described. All prepared derivatives were evaluated in vitro for their inhibitory activity against HDAC10 (from zebrafish) and human HDACs 1, 6, and 8 (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Compound <bold>2a</bold>, which incorporates an indole methylene capping group, demonstrated potent inhibition of HDAC10 with an IC<sub>50</sub> of 0.41&#8201;&#177;&#8201;0.02 nM (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). The tosylatated indole analogue, compound <bold>2c</bold>, also exhibtied nanomolar HDAC10 inhibition with an IC<sub>50</sub> of 4.5&#8201;&#177;&#8201;0.3 nM. Figure&#160;<xref rid="Fig2" ref-type="fig">3</xref>, shows that hydrophobic tosyl moiety does not interact with the rim of the HDAC10 binding site and instead remains fully exposed to the solvent. However, the removal of the methylene spacer between the primary amine and the benzhydroxamic acid moiety in analogs <bold>2d</bold> and <bold>2f</bold> result in a significant reduction in the inhibitory activity, with IC<sub>50</sub> of 290&#8201;&#177;&#8201;60 nM and 110&#8201;&#177;&#8201;10 nM, respectively. The loss of salt bridge interactions with D94 and E274, along with the cation-&#960; interaction with W205 in HDAC10, which were present in the other compounds reported in this study, is evident. As anticipated, only hydrogen bond interactions between the NH-group and D94 are observed (Figure <xref rid="MOESM1" ref-type="media">S1</xref>b and Figure <xref rid="MOESM1" ref-type="media">S1</xref>c).</p><p id="Par17">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Chemical structure and IC<sub>50</sub> values for synthesized compounds against HDAC10.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">ID</th><th align="left" colspan="1" rowspan="1">Structure</th><th align="left" colspan="1" rowspan="1">IC<sub>50</sub> drHDAC10&#8201;&#177;&#8201;SD [nM]</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>2a</bold>
</td><td align="left" colspan="1" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e689" xlink:href="41598_2025_2774_Figa_HTML.gif"/>
</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">0.41&#8201;&#177;&#8201;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2b</bold>
</td><td align="left" colspan="1" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e704" xlink:href="41598_2025_2774_Figb_HTML.gif"/>
</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">2.0&#8201;&#177;&#8201;0.1</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2c</bold>
</td><td align="left" colspan="1" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e719" xlink:href="41598_2025_2774_Figc_HTML.gif"/>
</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">4.5&#8201;&#177;&#8201;0.3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2d</bold>
</td><td align="left" colspan="1" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e734" xlink:href="41598_2025_2774_Figd_HTML.gif"/>
</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">290&#8201;&#177;&#8201;60</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2e</bold>
</td><td align="left" colspan="1" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e749" xlink:href="41598_2025_2774_Fige_HTML.gif"/>
</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">75&#8201;&#177;&#8201;12</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2f</bold>
</td><td align="left" colspan="1" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e764" xlink:href="41598_2025_2774_Figf_HTML.gif"/>
</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">110&#8201;&#177;&#8201;10</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2g</bold>
</td><td align="left" colspan="1" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e779" xlink:href="41598_2025_2774_Figg_HTML.gif"/>
</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">11&#8201;&#177;&#8201;1.0</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Tubastatin A</bold>
</td><td align="left" colspan="1" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e794" xlink:href="41598_2025_2774_Figh_HTML.gif"/>
</td><td char="&#xB1;" align="char" colspan="1" rowspan="1">50&#8201;&#177;&#8201;3</td></tr></tbody></table></table-wrap>
</p><p id="Par14">The second series of compounds comprise of 4-(1-piperazinyl)benzhydroxamic acid derivatives that bear a bicyclic aromatic moiety as a capping group. Compound <bold>2b</bold> exhibited potent HDAC10 inhibitory activity with an IC<sub>50</sub>&#8201;=&#8201;2.0&#8201;&#177;&#8201;0.1 nM. In contrast the methyltosylated indole derivative, compound <bold>2e</bold>, showed a decrease in the HDAC10 inhibitory activity with an IC<sub>50</sub> of 75&#8201;&#177;&#8201;12 nM (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Meanwhile, replacing the indole moiety in compound <bold>2b</bold> with aquinoline moiety yielded compound <bold>2g</bold>, which was slightly less potent, displaying an IC<sub>50</sub> value of 11&#8201;&#177;&#8201;1 nM.</p><p id="Par15">In conclusion of the structure-activity relationship (SAR) analysis, the absence of a strong basic amino group was found to reduce the inhibitory activity against HDAC10. Additionally, modifying the capping group with a hydrophobic tosyl moiety also led to a decrease in inhibitory activity.</p><p id="Par16">The preliminary structure-activity relationship (SAR) analysis revealed that the incorporation of bicyclic aromatic moiety enhanced HDAC10 inhibitory activity. We designed and synthesized seven compounds featuring various substituents at the cap position and linker. Among these, the benzhydroxamic acid derivative bearing an indole ring, compound <bold>2a</bold>, stood out as the most potent HDAC10 inhibitor, demonstrating exceptional enzyme inhibitory activity and selectivity toward HDAC10. Herein we introduce highly selective ligand <bold>2e</bold> for HDAC10 with nanomolar inhibitory activity.</p></sec><sec id="Sec6"><title>Enzymatic in vitro testing</title><p id="Par18">All the synthesized compounds were evaluated in vitro against zebrafish HDAC10 (drHDAC10), and human HDAC 1, 6, and 8 (details see Methods section). DrHDAC10 was chosen as the close homolog of human HDAC10 since it was found to be more stable and easier to express compared to the human HDAC10<sup><xref ref-type="bibr" rid="CR30">30</xref>&#8211;<xref ref-type="bibr" rid="CR32">32</xref></sup>. It&#8217;s worth mentioning that none of the compounds displayed potent inhibitory against class I HDACs. Data in Table&#160;<xref rid="Tab2" ref-type="table">2</xref> indicate that all compounds retained activity on HDAC10 comparable or even higher than the reference HDAC6/10 inhibitor Tubastatin A. We reported that the indole ring significantly affected the potency and selectivity towards HDAC10<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Compounds <bold>2a</bold> bearing a benzhydroxamic acid displays a highly potent inhibitory activity with IC<sub>50</sub> of 0.41&#8201;&#177;&#8201;0.02 nM towards HDAC10, but also potent against HDAC6 and moderately potent against HDAC8 with IC<sub>50</sub> value of 37&#8201;&#177;&#8201;2 and 350&#8201;&#177;&#8201;20 nM, respectively.</p><p id="Par19">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>In vitro selectivity of newly synthesized HDAC10 inhibitors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">ID</th><th align="left" colspan="1" rowspan="1">hHDAC1 IC<sub>50</sub> [nM]</th><th align="left" colspan="1" rowspan="1">hHDAC6 IC<sub>50</sub> [nM]</th><th align="left" colspan="1" rowspan="1">hHDAC8 IC<sub>50</sub> [nM]</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>2a</bold>
</td><td align="left" colspan="1" rowspan="1">4500&#8201;&#177;&#8201;200</td><td align="left" colspan="1" rowspan="1">37&#8201;&#177;&#8201;2</td><td align="left" colspan="1" rowspan="1">350&#8201;&#177;&#8201;20</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2b</bold>
</td><td align="left" colspan="1" rowspan="1">48.4%@1 &#181;M 90.6% @10 &#181;M</td><td align="left" colspan="1" rowspan="1">73&#8201;&#177;&#8201;3</td><td align="left" colspan="1" rowspan="1">74&#8201;&#177;&#8201;6</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2c</bold>
</td><td align="left" colspan="1" rowspan="1">22.2%@1 &#181;M 72.8% @10 &#181;M</td><td align="left" colspan="1" rowspan="1">51&#8201;&#177;&#8201;5</td><td align="left" colspan="1" rowspan="1">65.1%@1 &#181;M 97.3% @10 &#181;M</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2d</bold>
</td><td align="left" colspan="1" rowspan="1">1.3%@1 &#181;M 38.9% @10 &#181;M</td><td align="left" colspan="1" rowspan="1">53&#8201;&#177;&#8201;5</td><td align="left" colspan="1" rowspan="1">49.2%@1 &#181;M 98.9% @10 &#181;M</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2e</bold>
</td><td align="left" colspan="1" rowspan="1"><p>7.3%@1 &#181;M</p><p>67.2% @10 &#181;M</p></td><td align="left" colspan="1" rowspan="1"><p>35.3%@1 &#181;M</p><p>95% @10 &#181;M</p></td><td align="left" colspan="1" rowspan="1">26.9%@1 &#181;M 87.9% @10 &#181;M</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2f</bold>
</td><td align="left" colspan="1" rowspan="1">51.7%@1 &#181;M 91.4% @10 &#181;M</td><td align="left" colspan="1" rowspan="1">2.5&#8201;&#177;&#8201;0.3</td><td align="left" colspan="1" rowspan="1">210&#8201;&#177;&#8201;10</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2g</bold>
</td><td align="left" colspan="1" rowspan="1">32.1%@1 &#181;M 79.4% @10 &#181;M</td><td align="left" colspan="1" rowspan="1">130&#8201;&#177;&#8201;10</td><td align="left" colspan="1" rowspan="1">300&#8201;&#177;&#8201;20</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>TubastatinA</bold>
</td><td align="left" colspan="1" rowspan="1"><p>7.6% @1 &#181;M</p><p>29.9%@10 &#181;M</p></td><td align="left" colspan="1" rowspan="1">19&#8201;&#177;&#8201;1</td><td align="left" colspan="1" rowspan="1"><p>46.4% @1 &#181;M</p><p>84% @10 &#181;M</p></td></tr></tbody></table></table-wrap>
</p><p id="Par20">Compounds <bold>2b</bold> and <bold>2g</bold> showed a preference for HDAC10 (IC<sub>50</sub> 2.0&#8201;&#177;&#8201;0.1 and 11&#8201;&#177;&#8201;1 nM, respectively) compared with HDAC8 and HDAC6. As can be expected, compound <bold>2f</bold>, which only contains a weakly basic aromatic amine moiety, showed a significant decrease in the HDAC10 inhibitory activity and high preference and potency to HDAC6 with an IC<sub>50</sub> value of 2.5&#8201;&#177;&#8201;0.3 nM, which again highlights the importance of the protonated amine group to achieve high HDAC10 potency and selectivity.</p><p id="Par21">Meanwhile, compounds <bold>2c</bold> and <bold>2d</bold> showed a preference for class IIb enzymes (HDAC10 and 6) with no significant inhibition on HDAC1/8. HDAC6 is well documented, it plays a crucial role in microtubule deacetylation and regulation of PDL1 and further targets related to cancer immunotherapy<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>.</p><p id="Par22">In combination with the observed in vitro potency and selectivity of compounds <bold>2c</bold> and <bold>2d</bold>, both represent promising hits for further optimization. The lack of specific and potent HDAC10 inhibitors led to limited knowledge about the biological function of HDAC10<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. A more distinguished result showed by compound <bold>2e</bold> examined the inhibitory of compound <bold>2e</bold> revealed high selectivity with a novel nanomolar inhibitor toward HDAC10 (IC<sub>50</sub> 75&#8201;&#177;&#8201;12 nM).</p></sec><sec id="Sec7"><title>Cytotoxic activity</title><p id="Par23">All the synthesized compounds (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>) were screened at three different concentrations for their cytotoxicity towards a panel of four human solid tumor cell lines: melanoma (SK-MEL), epidermal carcinoma (KB), breast carcinoma (BT-549), and ovarian carcinoma (SK-OV-3). Moreover, non-cancer kidney cell lines (LLC-PK1 and VERO) were also included in the study.</p><p id="Par24">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Cytotoxicity of compounds towards a panel of cell lines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">ID</th><th align="left" colspan="4" rowspan="1">Cancer cell lines IC<sub>50</sub> &#181;M</th><th align="left" colspan="2" rowspan="1">Kidney cells IC<sub>50</sub> &#181;M</th></tr><tr><th align="left" colspan="1" rowspan="1">SK-MEL</th><th align="left" colspan="1" rowspan="1">KB</th><th align="left" colspan="1" rowspan="1">BT-549</th><th align="left" colspan="1" rowspan="1">SK-OV-3</th><th align="left" colspan="1" rowspan="1">LLC-PK1</th><th align="left" colspan="1" rowspan="1">Vero</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>2a</bold>
</td><td align="left" colspan="1" rowspan="1">NC</td><td align="left" colspan="1" rowspan="1">72.80&#8201;&#177;&#8201;2.40</td><td align="left" colspan="1" rowspan="1">NC</td><td align="left" colspan="1" rowspan="1">60.95&#8201;&#177;&#8201;14.36</td><td align="left" colspan="1" rowspan="1">NC</td><td align="left" colspan="1" rowspan="1">62.64&#8201;&#177;&#8201;2.39</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2b</bold>
</td><td align="left" colspan="1" rowspan="1">25.97&#8201;&#177;&#8201;3.62</td><td align="left" colspan="1" rowspan="1">12.13&#8201;&#177;&#8201;1.41</td><td align="left" colspan="1" rowspan="1">16.84&#8201;&#177;&#8201;3.63</td><td align="left" colspan="1" rowspan="1">11.42&#8201;&#177;&#8201;4.04</td><td align="left" colspan="1" rowspan="1">13.27&#8201;&#177;&#8201;1.41</td><td align="left" colspan="1" rowspan="1">5.99&#8201;&#177;&#8201;0.40</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2c</bold>
</td><td align="left" colspan="1" rowspan="1">15.12&#8201;&#177;&#8201;0.94</td><td align="left" colspan="1" rowspan="1">20.25&#8201;&#177;&#8201;0.32</td><td align="left" colspan="1" rowspan="1">16.46&#8201;&#177;&#8201;0.32</td><td align="left" colspan="1" rowspan="1">21.36&#8201;&#177;&#8201;1.89</td><td align="left" colspan="1" rowspan="1">16.57&#8201;&#177;&#8201;3.93</td><td align="left" colspan="1" rowspan="1">21.36&#8201;&#177;&#8201;1.27</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2d</bold>
</td><td align="left" colspan="1" rowspan="1">8.38&#8201;&#177;&#8201;2.11</td><td align="left" colspan="1" rowspan="1">13.32&#8201;&#177;&#8201;0.33</td><td align="left" colspan="1" rowspan="1">11.37&#8201;&#177;&#8201;0.16</td><td align="left" colspan="1" rowspan="1">12.63&#8201;&#177;&#8201;0.98</td><td align="left" colspan="1" rowspan="1">9.99&#8201;&#177;&#8201;0.49</td><td align="left" colspan="1" rowspan="1">50.52&#8201;&#177;&#8201;9.74</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2e</bold>
</td><td align="left" colspan="1" rowspan="1">8.82&#8201;&#177;&#8201;0.70</td><td align="left" colspan="1" rowspan="1">10.01&#8201;&#177;&#8201;0.70</td><td align="left" colspan="1" rowspan="1">9.71&#8201;&#177;&#8201;0.28</td><td align="left" colspan="1" rowspan="1">8.62&#8201;&#177;&#8201;0.42</td><td align="left" colspan="1" rowspan="1">8.82&#8201;&#177;&#8201;1.26</td><td align="left" colspan="1" rowspan="1">13.18&#8201;&#177;&#8201;1.82</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2f</bold>
</td><td align="left" colspan="1" rowspan="1">15.17&#8201;&#177;&#8201;1.21</td><td align="left" colspan="1" rowspan="1">9.72&#8201;&#177;&#8201;0.73</td><td align="left" colspan="1" rowspan="1">14.83&#8201;&#177;&#8201;2.65</td><td align="left" colspan="1" rowspan="1">10.91&#8201;&#177;&#8201;2.89</td><td align="left" colspan="1" rowspan="1">9.38&#8201;&#177;&#8201;0.25</td><td align="left" colspan="1" rowspan="1">3.92&#8201;&#177;&#8201;0.24</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2g</bold>
</td><td align="left" colspan="1" rowspan="1">&gt;&#8201;69.03</td><td align="left" colspan="1" rowspan="1">&gt;&#8201;69.03</td><td align="left" colspan="1" rowspan="1">&gt;&#8201;69.03</td><td align="left" colspan="1" rowspan="1">&gt;&#8201;69.03</td><td align="left" colspan="1" rowspan="1">&gt;&#8201;69.07</td><td align="left" colspan="1" rowspan="1">51.04&#8201;&#177;&#8201;1.95</td></tr><tr><td align="left" colspan="1" rowspan="1">Doxorubicin</td><td align="left" colspan="1" rowspan="1">2.52</td><td align="left" colspan="1" rowspan="1">2.30</td><td align="left" colspan="1" rowspan="1">3.44</td><td align="left" colspan="1" rowspan="1">2.01</td><td align="left" colspan="1" rowspan="1">2.34</td><td align="left" colspan="1" rowspan="1">&gt;&#8201;11</td></tr></tbody></table><table-wrap-foot><p>NC: No cytotoxicity up to 80 &#181;M. Values are represented as mean&#8201;&#177;&#8201;SD (<italic toggle="yes">n</italic>&#8201;=&#8201;3).</p></table-wrap-foot></table-wrap>
</p><p id="Par26">In the first screening, all compounds were tested at a concentration of 80 &#181;M by the MTT assay. The result showed all compounds had cytotoxicity at 80 &#181;M, and hence they were carried out for the second round of screening at a lower concentration. Data showed that all compounds displayed moderate cytotoxicity than the control compound, doxorubicin. Observing the dataset noted that all HDAC10 inhibitors were weakly toxic for LLC-PK1 and VERO kidney cell lines.</p></sec></sec><sec id="Sec8"><title>Molecular docking</title><sec id="Sec9"><title>Molecular modelling studies</title><p id="Par27">Docking studies have been conducted to elucidate the binding mode of the synthesized compounds in various HDAC isoforms, including HDAC1 (PDB ID: 5ICN), HDAC6 (PDB ID: 5EDU), HDAC8 (PDB ID: 2V5X) and drHDAC10 (PDB ID: 6UHU). To test the plausibility of the docking results, we compared them with several crystal structures of structurally related hydroxamic acids, including those we recently reported for drHDAC10.</p><p id="Par28"><bold>Tubastatin A</bold>, a known inhibitor of HDAC6 and HDAC10<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>, along with the newly synthesized inhibitors described here, were subjected to docking studies within the crystal structures of various HDACs. The binding modes were visually analyzed and the docking studies revealed that <bold>tubastatin A</bold> and the newly synthesized compounds can chelate the zinc ion in a bidentate manner in HDAC1, HDAC8, and HDAC10. On the other hand, in HDAC6, zinc chelation was observed to occur via the hydroxyl oxygen of the hydroxamate moiety in a monodentate fashion that has also been reported for other benzhydroxamic acids<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Docking solutions in all investigated HDAC isoforms (Figs.&#160;<xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig3" ref-type="fig">3</xref>, and Supporting information S1: Figures a-d) showed that the phenyl moiety of the linker was embedded in the hydrophobic lysine binding pocket. Furthermore, hydrogen bond interactions with the conserved residues H136/142/140, H137/143/141, and Y307/306/303 were observed in HDAC10, HDAC8, and HDAC1, respectively. In contrast, in HDAC6, the hydroxyl oxygen formed a water-mediated hydrogen bond with the conserved residues H610 and H611.</p><p id="Par32">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Predicted binding modes of compound <bold>1</bold> in different HDAC isoforms: (<bold>a</bold>) <bold>2a</bold> (teal sticks) in drHDAC10 (PDB ID 6UHU), (<bold>b</bold>) <bold>2a</bold> (violet sticks) in HDAC6 (PDB ID 5EDU), (<bold>c</bold>) <bold>2a</bold> (orange sticks) in HDAC8 (PDB ID 2V5X) (<bold>d</bold>) <bold>2a</bold> (magenta sticks) in HDAC1 (PDB ID 5ICN). The surface of the proteins is colored according to lipophilicity; green for hydrophobic and magenta for hydrophilic. Side chains of binding site residues are shown as white sticks and the catalytic zinc ion as an orange sphere. H-bond interactions are depicted as blue-dashed lines, salt bridge interactions as magenta-dashed lines, &#960;-&#960; interactions as orange-dashed lines, cation-&#960; interactions as green-dashed lines and zinc ion coordinationby the ligand as yellow-dashed lines.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1322" position="float" orientation="portrait" xlink:href="41598_2025_2774_Fig2_HTML.jpg"/></fig>
</p><p id="Par29">The predicted binding mode of compound <bold>2a</bold> in HDAC10 (Figs.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a, <xref rid="Fig2" ref-type="fig">2</xref>a) provides insights into its significant inhibitory activity against HDAC10. In addition to the previously mentioned hydrogen bond interactions with conserved tyrosine and histidine residues, the capping group exhibits &#960;-&#960; interactions with F204. Moreover, the protonated amine forms electrostatic and salt-bridge interactions with D94 and the gatekeeper residue E274, along with cation-&#960; interactions with W205 in HDAC10. These interactions resemble those observed in previously reported potent HDAC10 inhibitors and polyamine substrates<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. HDAC6 belongs to class IIa of HDACs. In comparison to HDAC10, the HDAC6 binding pocket exhibits specific differences, notably involving mutations D94/S568 and E274/L749. These variations in the binding pocket led to the docking results showing only a single hydrogen bond interaction between the protonated nitrogen of compound <bold>2a</bold> and S568. This observation could potentially explain the approximately 90-fold selectivity of HDAC10 over HDAC6 (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>b). In class I HDAC members (HDAC1 and HDAC8), variations in the gatekeeper residue at the top of the lysine binding tunnel (E274 in HDAC10 is replaced by M274 and L271 in HDAC1 and &#8722;&#8201;8, respectively) led to the loss of one electrostatic interaction with the protonated nitrogen of <bold>2a</bold> as well as the &#960;-&#960; interactions via the capping group, which were observed in HDAC10. The solvent-exposed capping groups together with the loss of electrostatic interaction with the gatekeeper are most likely the reason for the decrease in activity in both isoforms. Furthermore, the narrow binding pocket of HDAC1 due to the E274/L271 variation might lead to steric hindrance for the linker and capping groups of <bold>2a</bold> which may explain the higher loss of activity in this isoform (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>c, d).</p><p id="Par30">Similar results were observed for compounds <bold>2b</bold> and <bold>2g</bold>, which bear a piperazine linker instead of the aminomethyl linker of compound <bold>2a</bold>. Here, the protonated piperazine-<italic toggle="yes">NH</italic> was able to undergo two electrostatic interactions with D94 and E274 and cation-&#960; interactions with W205. Additionally, the capping groups showed similar &#960;-&#960; interaction with W205 in the HDAC10 binding pocket as observed for compound <bold>2a</bold> (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>a and Figure <xref rid="MOESM1" ref-type="media">S1</xref>d).</p><p id="Par31">Compounds lacking a strong basic amino group including compounds <bold>2d</bold> and <bold>2f</bold> showed a significant decrease in the HDAC10 inhibitory activity. This can be attributed to the loss of the salt bridge interactions with D94 and E274, and the cation-&#960; interaction with W205 in HDAC10, which were observed with the other compounds reported in this study. As expected, only hydrogen bond interactions between the NH-group and D94 are observed (Figure <xref rid="MOESM1" ref-type="media">S1</xref>b and Figure <xref rid="MOESM1" ref-type="media">S1</xref>c). These findings further emphasize the significance of the protonated nitrogen and its precise positioning in optimizing the binding interactions with HDAC10.</p><p id="Par33">The in vitro data presented in this study demonstrate that substituting the capping group with an additional tosyl moiety result in a decrease in HDAC10 inhibitory activity. Compound <bold>2c</bold> exhibits approximately a 10-fold reduction in HDAC10 inhibitory activity compared to compound <bold>2a</bold>, while compound <bold>2e</bold> shows an almost 38-fold decrease in activity compared to its unsubstituted counterpart, compound <bold>2b</bold>. The predicted binding mode of compound <bold>2e</bold> (Fig.&#160;<xref rid="Fig2" ref-type="fig">3</xref>b) was found to be similar to that of compound <bold>2b</bold> (Fig.&#160;<xref rid="Fig2" ref-type="fig">3</xref>a). However, an additional hydrogen bond via the sulfonyl group with N207 was observed in compound <bold>2e</bold>. Notably, the hydrophobic tosyl moiety does not interact with the rim of the HDAC10 binding site and remains fully exposed to the solvent. This observation could explain the decrease in HDAC10 inhibitory activity compared to compound <bold>2b</bold>.</p><p id="Par34">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Predicted binding modes of compounds, (<bold>a</bold>) <bold>2b</bold> (peach sticks) and (<bold>b</bold>) <bold>2e</bold> (teal sticks) in drHDAC10 (PDB ID 6UHU). The surface of the proteins is colored according to lipophilicity; green for hydrophobic and magenta for hydrophilic. Side chains of binding site residues are shown as white sticks and the catalytic zinc ion as orange spheres. H-bond interactions are depicted as blue-dashed lines, salt bridge interactions as magenta-dashed lines, &#960;-&#960; interactions as orange-dashed lines, cation-&#960; interactions as green-dashed lines, and coordination of the zinc ion by the ligand as yellow-dashed lines.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1456" position="float" orientation="portrait" xlink:href="41598_2025_2774_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec10"><title>Molecular dynamics (MD) simulations</title><p id="Par35">For the validation of the MD protocol, 100 ns MDs were applied to the available humanized drHDAC10 crystal structures (PDB IDs; 7U6B, 7U69, 7U6A, and 7U59, details in the Methods Section). Obtained RMSD plots from the molecular dynamic simulations revealed that the HDAC10-inhibitor structures (Figure S3c, Figure S4c, Figure S5c, and Figure S6c) are stable with an RMSD below 1.5 &#197; while the Zn ions generally show lower root mean square deviation (RMSD) values (Figure S3d, Figure S4d, Figure S5d and Figure S6d). Meanwhile, the ligand molecules tended to show higher fluctuations (Figure S3a, Figure S4a, Figure S5a, and Figure S6a) which was majorly attributed to the flexibility of the capping groups as observed in the ligand root mean square fluctuations (RMSF) plots (Figure S3b, Figure S4b, Figure S5b and Figure S6b).</p><p id="Par36">We further performed molecular dynamics simulation studies on the obtained docking pose of the most active compound <bold>2a</bold> in drHDAC10 to examine the stability of the predicted binding mode. The obtained protein-ligand complex was subjected to 100 ns MD simulation protocol three times using AMBER22, and the obtained trajectories were analyzed. RMSD plots showed that the protein structure and the zinc ion in the complex remained stable during the 100 ns simulation time in all three replicas with RMSD values below 1.5 &#197; (Figure S2a and Figure S2b). Meanwhile, the ligand RMSD plots (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>a) demonstrate that the ligand shows significant deviations from the predicted docking pose. Further analyses were performed to assess the stability of the obtained docking pose of compound <bold>2a</bold>, and analyze the causes behind the observed fluctuation. Examination of the ligand RMSF plots of compound <bold>2a</bold> (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>b) demonstrates that the zinc-binding hydroxamate group as well as the linker moiety are stable during the MD simulations with RMSF values&#8201;&lt;&#8201;1 &#197;. It&#8217;s worth noting that the interactions between the hydroxamate group and the zinc ion are maintained during the MD simulations as shown by the unchanged distances between the hydroxamate-<italic toggle="yes">O</italic> atoms and zinc ion (&lt;&#8201;2.5 &#197;; Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>c). Meanwhile, the indole-capping group displayed significantly high RMSF values that explains the strong deviations observed in the ligand RMSD plots. Clustering the obtained MD trajectories based on the RMSD of the ligand yielded three clusters with an occupancy&#8201;&gt;&#8201;10%. As can be demonstrated by the inspection of the obtained clusters (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>d), the indole capping group can occupy one of two different hydrophobic regions at the rim of the binding pocket: In two clusters (occupancy 55% and 15%, respectively), the capping group is undergoing hydrophobic interactions with I27, A28 and P29. In the third cluster (17% occupancy), the capping group is situated between F204 and W205 (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>C). The calculated data show, that the indole-capping group, despite showing strong fluctuations, is well accommodated at the entrance of the lysing binding pocket of HDAC10 where it undergoes hydrophobic interactions with surrounding residues.</p><p id="Par37">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>(<bold>a</bold>) RMSD plots of the compound <bold>2a</bold> heavy atoms in drHDAC10 (PDB ID 6UHU)-compound <bold>2a</bold> docked complexes for 3 repeated MD runs each for 100 ns. (<bold>b</bold>) RMSF plots of compound <bold>2a</bold> heavy atoms in drHDAC10 (PDB ID 6UHU)-compound <bold>2a</bold> docked complexes for three repeated MD runs each for 100 ns s (<bold>c</bold>). The measured distance between both oxygen atoms of the hydroxamate zinc binding moiety and catalytic zinc ion for three repeated MD runs. (<bold>d</bold>) Representative poses of the obtained three clusters with an occupancy&#8201;&gt;&#8201;10%, teal sticks for the first cluster (occupancy 55%), magenta sticks for the second cluster (occupancy 15%), and yellow sticks for the third cluster (occupancy 17%). Side chains of the relevant binding site residues are shown as white sticks and the catalytic zinc ion as orange spheres.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1526" position="float" orientation="portrait" xlink:href="41598_2025_2774_Fig4_HTML.jpg"/></fig>
</p></sec></sec></sec><sec id="Sec11"><title>Conclusion</title><p id="Par38">In this study, we synthesized novel bicyclic hydroxamic acid derivatives, characterized their inhibitory activity against class I, and class IIb HDACs. Our findings highlight compound <bold>2e</bold> as a potent and selective inhibitor of HDAC10, while compound <bold>2a</bold> exhibited the best inhibitory activity against HDAC10. Compound <bold>2f</bold> displayed a preference towards HDAC6, and compounds <bold>2c</bold> and <bold>2d</bold> demonstrated high selectivity towards class IIb HDACs over class I HDACs.</p><p id="Par39">Structural insights obtained from HDAC10&#8211;inhibitor complexes, along with the SAR study, provide a detailed understanding of the HDAC10 active site and highlight the critical structural features necessary for achieving potent and selective HDAC10 inhibition. Docking models with HDAC6 further elucidate the structural basis for HDAC10 selectivity over HDAC6, which is largely driven by the hydrophilic properties of the amino group integrated into the SAHA linker. Compounds lacking a strongly basic amino group exhibited a notable reduction in HDAC10 inhibitory activity. This decline can be explained by the loss of key interactions, such as salt bridges with D94 and E274, as well as cation-&#960; interactions with W205 in HDAC10, which were consistently observed with other compounds in this study. As anticipated, only hydrogen bond interactions between the NH-group and D94 were detected (Figure <xref rid="MOESM1" ref-type="media">S1</xref>b and Figure <xref rid="MOESM1" ref-type="media">S1</xref>c). These results underscore the importance of the protonated nitrogen and its precise spatial orientation in enhancing binding interactions with HDAC10, providing a strong rationale for the design of further selective HDAC10 inhibitors.</p><p id="Par40">On the other hand, molecular dynamics (MD) simulations reveal that the indole capping group can occupy one of two distinct hydrophobic regions at the rim of the binding pocket. In two clusters (with occupancies of 55% and 15%, respectively), the capping group engages in hydrophobic interactions with I27, A28, and P29. In a third cluster (17% occupancy), the capping group is positioned between F204 and W205 (Fig.&#160;<xref rid="Fig3" ref-type="fig">4</xref>C). The calculated data demonstrate that the indole capping group, despite exhibiting significant fluctuations, is well accommodated at the entrance of the lysine-binding pocket of HDAC10, where it participates in hydrophobic interactions with surrounding residues. This further supports the strategic design of inhibitors targeting HDAC10.</p></sec><sec id="Sec12"><title>Experimental</title><sec id="Sec13"><title>Chemistry</title><sec id="Sec14"><title>General</title><p id="Par41">Reagents and hydrous or anhydrous organic solvents were purchased from Sigma-Aldrich (Darmstadt, Germany) and Alfa Aesar Chemicals (Tewksbury, MA, USA) and were used without further purification. Reaction progress was monitored by thin-layer chromatography (TLC) on pre-coated 0.20&#160;mm silica gel GF Uniplates from Macherey-Nagel (D&#252;ren, Germany). The TLC plates were visualized using a 254&#160;nm UV lamp and chemical indicators such as ninhydrin, potassium permanganate (KMnO<sub>4</sub>), dinitrophenylhydrazine (DNP), green girasol, and anisaldehyde. Column chromatography was performed with 63&#8211;200 &#181;M silica gel with a 70&#8211;230 mesh size. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker BB 400&#160;MHz spectrometer. Chemical shifts (&#948;) are reported in ppm relative to tetramethyl silane (TMS) as an internal standard and coupling constants (<italic toggle="yes">J</italic>) are reported in Hz. The following abbreviations were used to denote multiplicity: s&#8201;=&#8201;singlet d&#8201;=&#8201;doublet t&#8201;=&#8201;triplet q&#8201;=&#8201;quartet dd&#8201;=&#8201;doublet of doublets dq&#8201;=&#8201;doublet of quartets m&#8201;=&#8201;multiplet.</p></sec><sec id="Sec15"><title>General procedure for the synthesis of HDACs inhibitor</title></sec><sec id="Sec220"><title>General synthesis methods</title><sec id="Sec20"><title>Preparation of 1-tosyl-1<italic toggle="yes">H</italic>-indole-3-carbaldehyde (2)</title><p id="Par44">This compound was prepared from 1<italic toggle="yes">H</italic>-indole-3-carbaldehyde and <italic toggle="yes">p</italic>-toluenesulfonyl chloride, according to the previously reported<sup><xref ref-type="bibr" rid="CR37">37</xref>&#8211;<xref ref-type="bibr" rid="CR39">39</xref></sup>.</p><p id="Par45">1<italic toggle="yes">H</italic>-indole-3-carbaldehyde (<bold>1</bold>) (1equiv., 3&#160;g, 20.7 mmol) was dissolved in anhydrous <italic toggle="yes">N</italic>, <italic toggle="yes">N</italic>&#8217;-Dimethylformamide (DMF, 30 mL). The solution was stirred under nitrogen for 15&#160;min in an ice bath. Sodium hydride (NaH) (1.1 equiv., 0.55&#160;g, 22.9 mmol) was then added, followed by the slow addition of 4-methylbenzenesulfonyl chloride (1.4 equiv., 5.52g, 28.8 mmol) after 10&#160;min. The reaction mixture was stirred overnight at room temperature. The reaction was quenched with distilled water (10 mL), and then a saturated sodium bicarbonate (NaHCO<sub>3</sub>) solution (10 mL). The product was extracted three time with dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>, 25mL each). The solvent was evaporated under reduced pressure, and the product was recrystallized using CH<sub>2</sub>Cl<sub>2</sub> (15mL) and hexane (10mL). The resulting light yellow crystals were washed with cold methanol. The yield was 75% (4.61&#160;g, 15.4 mmol), m.p 148&#8211;149&#160;&#176;C and R<sub>f</sub> 0.88 (Hexane: EtOAc, 1:1). <sup>1</sup>H-NMR (400&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS): &#948; 2.36(s, 3&#160;H, Ar-CH<sub>3</sub>), 7.29(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4&#160;Hz, 2&#160;H, H-12), 7.36(ddd, <italic toggle="yes">J</italic>&#8201;=&#8201;7.9, 7.3, 2.0&#160;Hz, 1H, H-6), 7.42(ddd, <italic toggle="yes">J</italic>&#8201;=&#8201;7.3, 8.2, 1.6&#160;Hz, 1H, H-7), 7.87(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4&#160;Hz, 2&#160;H, H-11), 7.97(dt, <italic toggle="yes">J</italic>&#8201;=&#8201;8.2, 2.0&#160;Hz, 1H, H-8), 8.26(s, 1H, H-2), 8.27(dt, <italic toggle="yes">J</italic>&#8201;=&#8201;7.9, 1.6&#160;Hz, 1H, H-5), 10.11(s, 1H, CHO).<sup>13</sup>C-NMR (100&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, 36&#160;&#176;C, TMS) &#948; 21.7(Ar-<italic toggle="yes">C</italic>H<sub>3</sub>), 113.3(C-8), 122.4(C-3), 122.6(C-5), 125.1(C-6), 126.30(C-4), 126.33(C-7), 127.3(C-11), 130.4(C-12), 134.3(C-9), 135.2(C-10), 136.3(C-2), 146.2 (C-13), 185.4(-<italic toggle="yes">C</italic>HO). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> [M&#8201;+&#8201;H]<sup>+</sup> calcd. for C<sub>16</sub>H<sub>14</sub>NO<sub>3</sub>S: 300.0694, found 300.0700.</p></sec><sec id="Sec19"><title>General procedure for preparation of ((1-tosyl-1<italic toggle="yes">H</italic>-indol-3-yl) methyl) amine carboxylate, (quinolin-3-ylmethyl)amine carboxylate or (1<italic toggle="yes">H</italic>-indol-3-yl)methyl)amine carboxylate derivatives (<bold>1a</bold>-<bold>g</bold>)</title><p id="Par47">To a solution of 1-tosyl-1<italic toggle="yes">H</italic>-indole-3-carbaldehyde (<bold>2</bold>) (1 equiv., 1.0&#8211;2.0 mmol), 3-quinolinecaboxaldehyde (<bold>3</bold>) (1 equiv., 1.5-2.0 mmol) or 1<italic toggle="yes">H</italic>-indole-3-carbaldehyde (<bold>1</bold>) (1.0 equiv, 1.5-3.0 mmol) in anhydrous dichloromethane (25 mL), the corresponding amine carboxylate (1.1-2.0 equiv., 1.1&#8211;4.5 mmol) was added. The reaction mixture was stirred under nitrogen for 2&#8211;4&#160;h at room temperature. Sodium triacetoxyborohydride ((CH<sub>3</sub>COO)<sub>3</sub>BHNa) (1.3-2.0 equiv., 1.3&#8211;4.5 mmol) was then added to the mixture in the ice bath, and the reaction was allowed to be stir overnight at room temperature. After completion, the mixture was quenched with distilled water (5 mL), followed by the addition of a saturated solution of sodium bicarbonate (5 mL). The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2&#8201;&#215;&#8201;20 mL), dried over anhydrous sodium sulfate Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude products were purified by column chromatography using silica gel with the appropriate eluent to afford the final products (<bold>1a-g</bold>).</p></sec><sec id="Sec21"><title>Preparation of ethyl 4-((((1<italic toggle="yes">H</italic>-indol-3-yl)methyl)amino)methyl)benzoate (<bold>1a</bold>)</title><p id="Par49">This compound was synthesized from 1<italic toggle="yes">H</italic>-indole-3-carbaldehyde (<bold>1</bold>) (1.0 equiv., 0.43&#160;g, 3.0 mmol), ethyl 4-(aminomethyl)benzoate (1.1 equiv., 0.59&#160;g, 3.3 mmol) and sodium triacetoxyborohydride ((CH<sub>3</sub>COO)<sub>3</sub>BHNa) (1.5 equiv., 0.95&#160;g, 4.5 mmol) following the general procedure and reaction conditions described above. The crude product was purified by column chromatography using silica gel with an eluent system of chloroform: methanol: ethyl acetate (20:1:1) to yield white crystals. The product was obtained in a 42% yield (0.39&#160;g, 1.26 mmol), m.<italic toggle="yes">p</italic>&#8201;=&#8201;90&#8211;91&#160;&#176;C, R<sub>f</sub> = 0.30 (CHCl<sub>3</sub>:MeOH: EtOAc 20:1:1). <sup>1</sup>H-NMR (400&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 1.44(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 3&#160;H, -OCH<sub>2</sub>CH<sub>3</sub>), 3.96(s, 2&#160;H, H-CH<sub>2</sub>N-benzylic), 4.04(d, <italic toggle="yes">J</italic>&#8201;=&#8201;0.8&#160;Hz, 2&#160;H, H-CH<sub>2</sub>N-pyrrol), 4.42(q, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 2&#160;H, -OCH<sub>2</sub>CH<sub>3</sub>), 7.13(m, 1H, H-2), 7.17(ddd, <italic toggle="yes">J</italic>&#8201;=&#8201;7.8, 7.0, 1.1&#160;Hz, 1H, H-6), 7.24(ddd, <italic toggle="yes">J</italic>&#8201;=&#8201;8.1, 7.0, 1.1&#160;Hz, 1H, H-7), 7.37(dt, <italic toggle="yes">J</italic>&#8201;=&#8201;8.1, 1.1&#160;Hz, 1H, H-8), 7.47(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.3&#160;Hz, 2&#160;H, H-11), 7.69(dt, <italic toggle="yes">J</italic>&#8201;=&#8201;7.8, 1.1, 1H, H-5), 8.06(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.3&#160;Hz, 2&#160;H, H-12), 8.45(s, 1H, H1-NH). <sup>13</sup>C-NMR (100&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 14.4(OCH<sub>2</sub><italic toggle="yes">C</italic>H<sub>3</sub>), 44.2(C-<italic toggle="yes">C</italic>H<sub>2</sub>N-pyrrol), 52.9(C-<italic toggle="yes">C</italic>H<sub>2</sub>N-benzylic), 61.0(O<italic toggle="yes">C</italic>H<sub>2</sub>CH<sub>3</sub>), 111.3(C-8), 114.4(C-3), 118.9(C-5), 119.6(C-6), 122.2(C-7), 122.9(C-2), 127.1(C-4), 128.1(C-11), 129.2(C-13), 129.7(C-12), 136.5(C-9), 145.7(C-10), 166.7(C&#8201;=&#8201;O). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> [M&#8201;+&#8201;Hac-H]<sup>+</sup> calcd. for C<sub>21</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub> 367.1663, found 367.2593. [M&#8201;+&#8201;H]<sup>+</sup> calcd. for C<sub>19</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub>, 309.1597, found 309.1585.</p></sec><sec id="Sec22"><title>Preparation of ethyl 4-(4-((1<italic toggle="yes">H</italic>-indol-3-yl)methyl)piperazin-1-yl)benzoate (<bold>1b</bold>)</title><p id="Par51">This compound was synthesized from 1<italic toggle="yes">H</italic>-indole-3-carbaldehyde (<bold>1</bold>) (1.0 equiv., 0.43&#160;g, 3.0 mmol), ethyl 4-(1-piperazinyl)benzoate (1.2 equiv., 0.84&#160;g, 3.6 mmol) and sodium triacetoxyborohydride ((CH<sub>3</sub>COO)<sub>3</sub>BHNa) (1.3 equiv., 0.83&#160;g, 3.9 mmol) following the general procedure and reaction conditions described above. The crude product was purified by column chromatography using silica gel with an eluent system of chloroform: methanol (10:1) to yield white crystals. The product was obtained in a 73% yield (0.8&#160;g, 2.19 mmol), m.<italic toggle="yes">p</italic>&#8201;=&#8201;175&#8211;176&#160;&#176;C, R<sub>f</sub> = 0.50 (CHCl<sub>3</sub>: MeOH, 10:1). <sup>1</sup>H-NMR (400&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 1.41(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 3&#160;H, -OCH<sub>2</sub>CH<sub>3</sub>), 2.69(dd, <italic toggle="yes">J</italic>&#8201;=&#8201;6.7, 3.1&#160;Hz, 4&#160;H, H-10), 3.35(dd, <italic toggle="yes">J</italic>&#8201;=&#8201;6.7, 2.8&#160;Hz, 4&#160;H, H-11), 3.82(s, 2&#160;H, H-CH<sub>2</sub>N), 4.37(q, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 2&#160;H, -OCH<sub>2</sub>CH<sub>3</sub>), 6.86(d, <italic toggle="yes">J</italic>&#8201;=&#8201;9.1&#160;Hz, 2&#160;H, H-13), 7.17(m, 1H, H-2), 7.18(m, 1H, H-6), 7.25(m, 1H, H-7), 7.38(dd, <italic toggle="yes">J</italic>&#8201;=&#8201;8.0, 1.2&#160;Hz, 1H, H-8), 7.80(dd, <italic toggle="yes">J</italic>&#8201;=&#8201;7.8, 1.2&#160;Hz, 1H, H-5), 7.96(d, <italic toggle="yes">J</italic>&#8201;=&#8201;9.1&#160;Hz, 2&#160;H, H-14), 8.47(s, 1H, -NH). <sup>13</sup>C-NMR (100&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 14.5(OCH<sub>2</sub><italic toggle="yes">C</italic>H<sub>3</sub>), 47.5(C-11), 52.7(C-10), 53.6(C-<italic toggle="yes">C</italic>H<sub>2</sub>N), 60.4(O<italic toggle="yes">C</italic>H<sub>2</sub>CH<sub>3</sub>), 111.2(C-8), 112.0(C-3), 113.6(C-13), 119.5(C-5), 119.6(C-6), 119.9(C-15), 122.1(C-7), 124.0(C-2), 128.0(C-4), 131.2(C-14), 136.3(C-9), 154.2(C-12), 166.9(C&#8201;=&#8201;O). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> [M&#8201;+&#8201;H]<sup>+</sup> calcd. for C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub>, 364.2020, found 364.2050.</p></sec><sec id="Sec23"><title>Preparation of ethyl 4-((((1-tosyl-1<italic toggle="yes">H</italic>-indol-3-yl)methyl)amino)methyl)benzoate (<bold>1c</bold>)</title><p id="Par53">This compound was synthesized from 1-tosyl-1<italic toggle="yes">H</italic>-indole-3-carbaldehyde (<bold>2</bold>) (1.0 equiv., 0.45&#160;g, 1.50 mmol), ethyl 4-(aminomethyl)benzoate (1.1 equiv., 0.30&#160;g, 1.65 mmol) and sodium triacetoxyborohydride ((CH<sub>3</sub>COO)<sub>3</sub>BHNa) (1.5 equiv, 0.48&#160;g, 2.25 mmol) following the general procedure and reaction conditions described above. The crude product was purified by column chromatography using silica gel with an eluent system of chloroform: methanol (98:2), yielding white crystals with a 45% yield (0.31&#160;g, 0.7 mmol), m.<italic toggle="yes">p</italic>&#8201;=&#8201;110&#8211;112&#160;&#176;C, R<sub>f</sub> = 0.54 (CHCl<sub>3</sub>:MeOH, 98:2). <sup>1</sup>H-NMR (400&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 1.42(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 3&#160;H, -OCH<sub>2</sub>CH<sub>3</sub>), 2.33(s, 3&#160;H, Ar-CH3), 3.89(s, 2&#160;H, H-16), 3.92(s, 2&#160;H, H-14), 4.40(q, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 2&#160;H, -OCH2CH3), 7.21(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.2&#160;Hz, 2&#160;H, H-12), 7.27(ddd, <italic toggle="yes">J</italic>&#8201;=&#8201;8.2, 7.8, 1.0&#160;Hz, 1H, H-7), 7.34(ddd, <italic toggle="yes">J</italic>&#8201;=&#8201;8.2, 7.3, 1.3&#160;Hz, 1H, H-6), 7.43(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.2&#160;Hz, 2&#160;H, H-18), 7.53(s, 1H, H-2), 7.58(dt, <italic toggle="yes">J</italic>&#8201;=&#8201;7.8, 1.3,, 1H, H-8), 7.78(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.2&#160;Hz, 2&#160;H, H-11), 8.02(m,1H, H-5), 8.04(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.2&#160;Hz, 2&#160;H, H-19).<sup>13</sup>C-NMR (100&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 14.4(OCH<sub>2</sub><italic toggle="yes">C</italic>H<sub>3</sub>), 21.6( Ar-<italic toggle="yes">C</italic>H<sub>3</sub>), 43.9(C-14), 53.0(C-16), 60.9(O<italic toggle="yes">C</italic>H<sub>2</sub>CH<sub>3</sub>), 113.8(C-5), 119.8 (C-8), 121.3(C-3), 123.2(C-7), 123.9(C-2), 124.9(C-6), 126.8(C-11), 128.0(C-18), 129.3(C-20), 129.8(C-19), 129.9(C-12), 130.3(C-4), 135.3(C-10), 135.5(C-9), 144.9(C-13), 145.3(C-17), 166.6(C&#8201;=&#8201;O). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> [2&#160;M&#8201;+&#8201;H]<sup>+</sup> calcd. for C<sub>52</sub>H<sub>53</sub>N<sub>4</sub>O<sub>8</sub>S<sub>2</sub> 925.3299, found 925.3390. [M&#8201;+&#8201;Na]<sup>+</sup> calcd for C<sub>26</sub>H<sub>26</sub>NaN<sub>2</sub>O<sub>4</sub>S 485.1506, found 485.1539.</p></sec><sec id="Sec24"><title>Preparation of ethyl 4-(((1-tosyl-1<italic toggle="yes">H</italic>-indol-3-yl) methyl) amino) benzoate (<bold>1d</bold>)</title><p id="Par55">This compound was synthesized from 1-tosyl-1<italic toggle="yes">H</italic>-indole-3-carbaldehyde (<bold>2</bold>) (1.0 equiv., 0.45&#160;g, 1.50 mmol), Ethyl 4-aminobenzoate (1.2 equiv., 0.30&#160;g, 1.8 mmol) and sodium triacetoxyborohydride ((CH<sub>3</sub>COO)<sub>3</sub>BHNa) (2 equiv., 0.63&#160;g, 2.0 mmol) following the general procedure and reaction conditions described above. The crude product was purified by column chromatography using silica gel with an eluent system of chloroform: ethyl acetate (4:1), yielding white crystals with an 85% yield (0.57&#160;g, 1.3 mmol), 154&#8211;155&#160;&#176;C, R<sub>f</sub> = 0.85 (CHCl<sub>3</sub>: EtOAc, 4 :1). <sup>1</sup>H-NMR (400&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 1.40(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 3&#160;H, -OCH<sub>2</sub>CH<sub>3</sub>), 2.35(s, 3&#160;H, Ar-CH<sub>3</sub>), 4.35(q, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 2&#160;H, -OCH<sub>2</sub>CH<sub>3</sub>), 4.47(d, <italic toggle="yes">J</italic>&#8201;=&#8201;1.2&#160;Hz, 2&#160;H, -NCH<sub>2</sub>), 6.60(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.7&#160;Hz, 2&#160;H, H-15), 7.19(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4&#160;Hz, 2&#160;H, H-12), 7.26(ddd, <italic toggle="yes">J</italic>&#8201;=&#8201;8.5, 7.7, 1.0&#160;Hz, 1H, H-7), 7.36(ddd, <italic toggle="yes">J</italic>&#8201;=&#8201;8.5, 7.2, 1.3&#160;Hz, 1H, H-6), 7.50(s, 1H, H-2), 7.53(m, 1H, H-8), 7.70(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4&#160;Hz, 2&#160;H, H-11), 7.89(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.7&#160;Hz, 2&#160;H, H-16), 8.04(m, 1H, H-5). <sup>13</sup>C-NMR (100&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 14.5(OCH<sub>2</sub><italic toggle="yes">C</italic>H<sub>3</sub>), 21.6(Ar-<italic toggle="yes">C</italic>H<sub>3</sub>), 39.2(N-CH<sub>2</sub>), 60.3(O<italic toggle="yes">C</italic>H<sub>2</sub>CH<sub>3</sub>), 111.8(C-15), 114.0(C-5), 119.2(C-17), 119.5(C-8), 119.7(C-3), 123.4(C-7), 124.3(C-2), 125.1(C-6), 126.8(C-11), 129.6(C-4), 129.9 (C-12), 131.5(C-16), 135.9(C-10), 135.6(C-9), 145.1(C-13), 151.5(C-14), 166.9(C&#8201;=&#8201;O). HRMS m/z [M&#8201;+&#8201;Cl]<sup>+</sup> calcd for C25H24ClN2O4S 483.1146, found 483.1073.</p></sec><sec id="Sec25"><title>Preparation of ethyl 4-(4-((1-tosyl-1<italic toggle="yes">H</italic>-indol-3-yl) methyl) piperazin-1-yl) benzoate (<bold>1e</bold>)</title><p id="Par57">This compound was synthesized from 1-tosyl-1<italic toggle="yes">H</italic>-indole-3-carbaldehyde (<bold>2</bold>) (1.0 equiv, 0.45&#160;g, 1.50 mmol), ethyl 4-(1-piperazinyl)benzoate (1.2 equiv., 0.42&#160;g, 1.8 mmol) and sodium triacetoxyborohydride ((CH<sub>3</sub>COO)<sub>3</sub>BHNa) (1.3 equiv., 0.41&#160;g, 1.95 mmol) following the general procedure and reaction conditions described above. The crude product was purified by column chromatography using silica gel with an eluent system of chloroform: ethyl acetate (3:1), yielding white crystals with an 78% yield (0.6&#160;g, 1.2 mmol), m.<italic toggle="yes">p</italic>&#8201;=&#8201;166&#8211;167&#160;&#176;C, R<sub>f</sub> = 0.62 (CHCl<sub>3</sub>:EtOAc, 3:1). <sup>1</sup>H-NMR (400&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 1.39(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 3&#160;H, -OCH<sub>2</sub><italic toggle="yes">CH</italic><sub><italic toggle="yes">3</italic></sub>), 2.33(s, 3&#160;H, Ar-<italic toggle="yes">CH</italic><sub><italic toggle="yes">3</italic></sub>), 2.60(m, 4&#160;H, H-14), 3.31(m, 4&#160;H, H-15), 3.69(s, 2&#160;H, H-NC<italic toggle="yes">H</italic><sub>2</sub>), 4.36(q, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 2&#160;H, -O<italic toggle="yes">CH</italic><sub><italic toggle="yes">2</italic></sub>CH<sub>3</sub>), 6.86(d, <italic toggle="yes">J</italic>&#8201;=&#8201;9.1&#160;Hz, 2&#160;H, H-17), 7.21(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4&#160;Hz, 2&#160;H, H-12), 7.25(m, 1H, H-7), 7.35(ddd, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4, 7.2, 1.3&#160;Hz, 1H, H-6), 7.56(s, 1H, H-2), 7.74(dt, <italic toggle="yes">J</italic>&#8201;=&#8201;7.8, 1.3&#160;Hz, 1H, H-8), 7.80(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4&#160;Hz, 2&#160;H, H-11), 7.96(d, <italic toggle="yes">J</italic>&#8201;=&#8201;9.1&#160;Hz, 2&#160;H, H-18), 8.04(dt, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4, 1.0&#160;Hz, 1H, H-5). <sup>13</sup>C-NMR (100&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 14.5(OCH<sub>2</sub><italic toggle="yes">C</italic>H<sub>3</sub>), 21.6(Ar-<italic toggle="yes">C</italic>H<sub>3</sub>), 47.5(C-15), 52.8(C-14), 53.4(C-N<italic toggle="yes">C</italic>H<sub>2</sub>), 60.4(O<italic toggle="yes">C</italic>H<sub>2</sub>CH<sub>3</sub>), 113.6(C-17), 113.7(C-5), 119.2(C-19), 120.0(C-3), 120.6(C-8), 123.2(C-7), 124.9(C-2), 124.9(C-6), 126.8(C-11), 129.9(C-12), 130.8(C-4), 131.2(C-18), 135.3(C-10), 135.5(C-9), 145.0(C-13), 154.1(C-16), 166.7 (C&#8201;=&#8201;O). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> [M&#8201;+&#8201;H]<sup>+</sup> calcd. for C<sub>29</sub>H<sub>32</sub>N<sub>3</sub>O<sub>4</sub>S 518.2114, found 518.2221. [M&#8201;+&#8201;Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>31</sub>NaN<sub>3</sub>O<sub>4</sub>S 540.1928, found 540.1935.</p></sec><sec id="Sec26"><title>Preparation of ethyl 4-((quinolin-3-ylmethyl)amino)benzoate (<bold>1f</bold>)</title><p id="Par59">This compound was synthesized from 3-quinolinecaboxaldehyde (<bold>3</bold>) (1 equiv., 0.314&#160;g, 2.0 mmol), ethyl 4-aminobenzoate (1.1 equiv., 0.36&#160;g, 2.2 mmol) and sodium triacetoxyborohydride ((CH<sub>3</sub>COO)<sub>3</sub>BHNa) (1.5 equiv., 0.64&#160;g, 3.0 mmol) following the general procedure and reaction conditions described above<sup><xref ref-type="bibr" rid="CR40">40</xref>&#8211;<xref ref-type="bibr" rid="CR42">42</xref></sup>. The crude product was purified by column chromatography using silica gel with an eluent system of chloroform: ethyl acetate (4:1), yielding white crystals with an 66% yield (0.4&#160;g, 1.3 mmol), m.<italic toggle="yes">p</italic>&#8201;=&#8201;135&#8211;136&#160;&#176;C, R<sub>f</sub> = 0.38(CHCl<sub>3</sub>:EtOAc, 4:1). <sup>1</sup>H-NMR (400&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 1.35(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 3&#160;H, -OCH<sub>2</sub><italic toggle="yes">CH</italic><sub><italic toggle="yes">3</italic></sub>), 4.31(q, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 2&#160;H, -O<italic toggle="yes">CH</italic><sub><italic toggle="yes">2</italic></sub>CH<sub>3</sub>), 4.58(d, <italic toggle="yes">J</italic>&#8201;=&#8201;4.5&#160;Hz, 2&#160;H, -N<italic toggle="yes">CH</italic><sub><italic toggle="yes">2</italic></sub>), 4.92(s, br, <italic toggle="yes">-</italic>N<italic toggle="yes">H</italic>), 6.64(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.8&#160;Hz, 2&#160;H, H-12), 7.55(ddd, <italic toggle="yes">J</italic>&#8201;=&#8201;8.1, 6.9, 1.2&#160;Hz, 1H, H-7), 7.71(ddd, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4, 6.9, 1.5&#160;Hz, 1H, H-8), 7.76(dd, <italic toggle="yes">J</italic>&#8201;=&#8201;8.1, 1.5&#160;Hz, 1H, H-6), 7.89(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.8&#160;Hz, 2&#160;H, H-13), 8.07(dd, <italic toggle="yes">J</italic>&#8201;=&#8201;2.2, 1.0&#160;Hz, 1H, H-4), 8.11(dt, <italic toggle="yes">J</italic>&#8201;=&#8201;8.5, 1.0, 1.0&#160;Hz, 1H, H-9), 8.90(d, <italic toggle="yes">J</italic>&#8201;=&#8201;2.2&#160;Hz, 1H, H-2). <sup>13</sup>C-NMR (100&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 14.5(OCH<sub>2</sub><italic toggle="yes">C</italic>H<sub>3</sub>), 45.4(-N<italic toggle="yes">C</italic>H<sub>2</sub>), 60.3(O<italic toggle="yes">C</italic>H<sub>2</sub>CH<sub>3</sub>), 111.8(C-12), 119.5(C-14), 127.1(C-7), 127.7(C-6), 127.9(C-5), 129.1(C-9), 129.2(C-8), 131.3(C-3), 131.6(C-13), 134.1(C-4), 147.5(C-10), 150.3(C-2), 151.3(C-11), 166.8(C&#8201;=&#8201;O). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> [M&#8201;+&#8201;H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub> 307.1441, found 307.1473.</p></sec><sec id="Sec27"><title>Preparation of ethyl 4-(4-(quinolin-3-ylmethyl)piperazin-1-yl)benzoate (<bold>1g</bold>)</title><p id="Par61">This compound was synthesized from 3-quinolinecaboxaldehyde (<bold>3</bold>) (1 equiv., 0.236&#160;g, 1.50 mmol), ethyl 4-(1-piperazinyl)benzoate (1.2 equiv., 0.42&#160;g, 1.8 mmol), and sodium triacetoxyborohydride ((CH<sub>3</sub>COO)<sub>3</sub>BHNa) (1.3 equiv., 0.42&#160;g, 1.95 mmol) following the general procedure and reaction conditions as described above. The crude product was purified by column chromatography using silica gel with an eluent system of chloroform: methanol (94:6), yielding white crystals with a 63% yield (0.35&#160;g, 1 mmol), m.<italic toggle="yes">p</italic>&#8201;=&#8201;153&#8211;155&#160;&#176;C, R<sub>f</sub> = 0.68 (CHCl<sub>3</sub>:MeOH, 94:6). <sup>1</sup>H-NMR (400&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 1.34(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 3&#160;H, -OCH<sub>2</sub><italic toggle="yes">CH</italic><sub><italic toggle="yes">3</italic></sub>), 2.60(t, <italic toggle="yes">J</italic>&#8201;=&#8201;5.0&#160;Hz, 4&#160;H, H-11), 3.29(t, <italic toggle="yes">J</italic>&#8201;=&#8201;5.0&#160;Hz, 4&#160;H, H-12), 3.69(s, 2&#160;H, C<italic toggle="yes">H</italic><sub>2</sub>N), 4.30(q, <italic toggle="yes">J</italic>&#8201;=&#8201;7.1&#160;Hz, 2&#160;H, -O<italic toggle="yes">CH</italic><sub><italic toggle="yes">2</italic></sub>CH<sub>3</sub>), 6.81(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.7&#160;Hz, 2&#160;H, H-14), 7.52(t, <italic toggle="yes">J</italic>&#8201;=&#8201;8.3&#160;Hz, 1H, H-7), 7.68(ddd, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4, 6.6, 1.4&#160;Hz, 1H, H-8), 7.79(dd, <italic toggle="yes">J</italic>&#8201;=&#8201;8.3, 1.4&#160;Hz, 1H, H-6), 7.91(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.7&#160;Hz, 2&#160;H, H-15), 8.05(d, <italic toggle="yes">J</italic>&#8201;=&#8201;2.1&#160;Hz, 1H, H-4), 8.11(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4&#160;Hz, 1H, H-9), 8.92(d, <italic toggle="yes">J</italic>&#8201;=&#8201;2.1&#160;Hz, 1H, H-2). <sup>13</sup>C-NMR (100&#160;MHz, CDCl<sub>3</sub>-<italic toggle="yes">d</italic>, TMS) &#948; 14.5(OCH<sub>2</sub><italic toggle="yes">C</italic>H<sub>3</sub>), 47.5(C-12), 52.8(C-11), 60.3(O<italic toggle="yes">C</italic>H<sub>2</sub>CH<sub>3</sub>), 60.4(N<italic toggle="yes">C</italic>H<sub>2</sub>), 113.6(C-14), 120.1(C-16), 126.8(C-7), 127.6(C-6), 127.9(C-5), 129.2(C-8), 129.2(C-9), 130.7(C-3), 131.1(C-15), 135.7(C-4), 147.6(C-10), 152.0(C-2), 154.0(C-13), 166.6(C&#8201;=&#8201;O). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> [M&#8201;+&#8201;H]<sup>+</sup> calcd. for C<sub>23</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub> 376.2020, found 376.2038.</p></sec><sec id="Sec28"><title>General procedure for preparation of corresponding hydroxamic acid derivatives of (<bold>2a</bold>-<bold>g</bold>)</title><p id="Par63">To a solution of benzoate derivatives (<bold>1a-g</bold>) (1 equiv., 0.27&#8211;0.45 mmol) in a mixture of anhydrous dichloromethane and methanol (1:2, 6 mL) at 0&#160;&#176;C, hydroxylamine (50 wt % in water, 7.99&#8211;13.37 mmol, 30 equiv.) was added, followed by the addition of sodium hydroxide (1.08&#8211;2.25 mmol, 4.0&#8211;5.0&#160;eq). The reaction mixture was allowed to warm to room temperature and stirred for 24&#160;h. Then the solvent was removed under reduced pressure, and the obtained solid was dissolved in water. The pH of the solution was adjusted to 7 using 1&#160;N HCl. The resulting precipitate was filtered and dried under a high vacuum, and then the crude products were purified by column chromatography using silica gel with the appropriate eluent or soaking with dichloromethane to give the final products (<bold>2a-g</bold>).</p></sec><sec id="Sec29"><title>Preparation of 4-((((1<italic toggle="yes">H</italic>-indol-3-yl)methyl)amino)methyl)-<italic toggle="yes">N</italic>-hydroxybenzamide (<bold>2a</bold>)</title><p id="Par65">Compound <bold>2a</bold> was synthesized from <bold>1a</bold> (0.10&#160;g, 0.32 mmol, 1 equiv.), hydroxylamine (50 wt % in water, 0.64 mL, 0.32&#160;g, 9.60 mmol, 30 equiv.) and sodium hydroxide (0.05&#160;g, 1.28 mmol, 4.0 equiv.) following the general procedure and reaction conditions described above. The crude product was purified by soaking with dichloromethane to yield compound <bold>2a</bold> as white crystals. The yield was 52% (49&#160;mg, 0.17 mmol), m.<italic toggle="yes">p</italic>&#8201;=&#8201;158&#8211;160&#160;&#176;C. <sup>1</sup>H-NMR (400&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948; 3.80(s, 2&#160;H, H-C<italic toggle="yes">H</italic><sub>2</sub>N-benzylic), 3.86(d, <italic toggle="yes">J</italic>&#8201;=&#8201;0.8&#160;Hz, 2&#160;H, H-C<italic toggle="yes">H</italic><sub>2</sub>N-pyrrol), 6.99(s, 1H, H-2), 7.08(m, 1H, H-6), 7.25(m, 1H, H-7), 7.36(m, 1H, H-8), 7.45(m, 2&#160;H, H-11), 7.61(m, 1H, H-5), 7.74(m, 2&#160;H, H-12), 10.91(s, 1H, -OH). <sup>13</sup>C-NMR (101&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948; 44.2(C-<italic toggle="yes">C</italic>H<sub>2</sub>N-pyrrol), 52.4(C-<italic toggle="yes">C</italic>H<sub>2</sub>N-benzylic), 111.8(C-8), 113.9(C-3), 118.7(C-2), 119.3(C-5), 121.4(C-6), 124.0(C-7), 127.2(C-12), 127.5(C-4), 128.3(C-11), 131.5(C-13), 136.9(C-9), 144.9(C-10), 164.7(C&#8201;=&#8201;O). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 294.1250 [M-H]<sup>+</sup> (calc for C<sub>17</sub>H<sub>16</sub>N<sub>3</sub>O<sub>2</sub>, 294.1242), 130.0656 [M-C<sub>8</sub>H<sub>9</sub>N<sub>2</sub>O<sub>2</sub>]<sup>+</sup> (calc for C<sub>9</sub>H<sub>8</sub>N, 130.0657).</p></sec><sec id="Sec30"><title>Preparation of 4-(4-((1<italic toggle="yes">H</italic>-indol-3-yl)methyl)piperazin-1-yl)-<italic toggle="yes">N</italic>-hydroxybenzamide (<bold>2b</bold>)</title><p id="Par67">Compound <bold>2b</bold> was synthesized from <bold>1b</bold> (0.10&#160;g, 0.27 mmol, 1 equiv.), hydroxylamine (50 wt % in water, 0.52 mL, 0.26&#160;g, 8.25 mmol, 30 equiv.) and sodium hydroxide (0.04&#160;g, 1.08 mmol, 4.0 equiv.) following the general procedure and reaction conditions described above. The crude product was purified by soaking with dichloromethane to afford <bold>2b</bold> as white crystals. The yield was 53% (50&#160;mg, 0.14 mmol), m.<italic toggle="yes">p</italic>&#8201;=&#8201;155&#8211;157&#160;&#176;C. <sup>1</sup>H-NMR (400&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948; 2.53(m, 4&#160;H, H-10), 3.20(m, 4&#160;H, H-11), 3.72(s, 2&#160;H, H-C<italic toggle="yes">H</italic><sub>2</sub>N), 6.87(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.9&#160;Hz, 2&#160;H, H-13), 7.00(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.4&#160;Hz, 1H, H-6), 7.08(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.5&#160;Hz, 1H, H-7), 7.27(s, 1H, H-2), 7.37(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.0&#160;Hz, 1H, H-8), 7.57(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.3&#160;Hz, 2&#160;H, H-14), 7.62(d, <italic toggle="yes">J</italic>&#8201;=&#8201;7.9&#160;Hz, 1H, H-5), 8.81(brs, 1H, -(N<italic toggle="yes">H</italic>)C&#8201;=&#8201;O), 10.93(s, 1H, NH(Ar)), 10.96(s, 1H, OH). <sup>13</sup>C-NMR (101&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948; 47.7(C-11), 52.7(C-10), 53.6(C-<italic toggle="yes">C</italic>H<sub>2</sub>N), 110.9(C-3), 111.8(C-8), 114.1(C-13), 118.9(C-6), 119.5(C-5), 121.4(C-7), 122.1(C-15), 125.2(C-2), 128.1(C-4), 128.5(C-14), 136.7(C-9), 153.2(C-12). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> [M-H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub> 349.1670, found 349.1678. [M&#8201;+&#8201;Cl<sup>35</sup>]<sup>+</sup> calcd for C<sub>20</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>2</sub> 385.1437, found 385.1442.</p></sec><sec id="Sec31"><title>Preparation of <italic toggle="yes">N</italic>-hydroxy-4-((((1-tosyl-1<italic toggle="yes">H</italic>-indol-3-yl)methyl)amino)methyl) benzamide (<bold>2c</bold>)</title><p id="Par69">Compound <bold>2c</bold> was synthesized from <bold>1c</bold> (0.20&#160;g, 0.43mmol, 1equiv.), hydroxylamine (50 wt % in water, 0.85mL, 0.42&#160;g, 12.90mmol, 30equiv.) and sodium hydroxide (0.086&#160;g, 2.15 mmol, 5.0 equiv.) following the general procedure and reaction conditions described above. The crude product was purified by using silica gel with an eluent system of dichloromethane: methanol (98.7:1.3) to yield <bold>2c</bold> as light-pink crystals. The yield was 37% (71&#160;mg, 0.16 mmol), m.<italic toggle="yes">p</italic>&#8201;=&#8201;151&#8211;153&#160;&#176;C, R<sub>f</sub> = 0.49 (CH<sub>2</sub>Cl<sub>2</sub>:MeOH (87:13)). <sup>1</sup>H-NMR (400&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948; 2.28(s, 3&#160;H, Ar-<italic toggle="yes">CH</italic><sub><italic toggle="yes">3</italic></sub>), 3.75(s, 2&#160;H, -N<italic toggle="yes">CH</italic><sub><italic toggle="yes">2</italic></sub>-16), 3.80(s, 2&#160;H, -N<italic toggle="yes">CH</italic><sub><italic toggle="yes">2</italic></sub>-14), 7.25(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.5&#160;Hz, 7.5&#160;Hz, 1H, H-7), 7.34(d, <italic toggle="yes">J</italic>&#8201;=&#8201;7.9&#160;Hz, 2&#160;H, H-12), 7.35(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.4&#160;Hz, 1H, H-6), 7.41(d, <italic toggle="yes">J</italic>&#8201;=&#8201;7.8&#160;Hz, 2&#160;H, H-18), 7.65(d, <italic toggle="yes">J</italic>&#8201;=&#8201;7.5&#160;Hz, 1H, H-8), 7.67(s, 1H, H-2), 7.75(d, <italic toggle="yes">J</italic>&#8201;=&#8201;7.8&#160;Hz, 2&#160;H, H-19), 7.83(d, <italic toggle="yes">J</italic>&#8201;=&#8201;7.9&#160;Hz, 2&#160;H, H-11), 7.93(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.2&#160;Hz, 1H, H-5), 9.04(brs, 1H, -((CO)N<italic toggle="yes">H</italic>), 11.17(brs, 1H, -O<italic toggle="yes">H</italic>). <sup>13</sup>C-NMR (101&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948; 21.5( Ar-<italic toggle="yes">C</italic>H<sub>3</sub>), 43.5(N-<italic toggle="yes">C</italic>H<sub>2</sub>-14), 52.4(N-<italic toggle="yes">C</italic>H<sub>2</sub>-16), 113.7(C-5), 120.8(C-8), 122.5(C-3), 123.7(C-7), 124.5(C-2), 125.2(C-6), 127.1(C-11), 127.3(C-19), 128.3(C-18), 130.6(C-12), 130.6(C-20), 131.6(C-4), 134.6(C-10), 135.2(C-9), 144.5(C-13), 145.8(C-17), 164.6(C&#8201;=&#8201;O). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> [M-H]<sup>+</sup> calcd. for C<sub>24</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub>S 448.1336, found 448.1342. [2&#160;M&#8201;+&#8201;H]<sup>+</sup> calcd for C<sub>48</sub>H<sub>45</sub>N<sub>6</sub>O<sub>8</sub>S<sub>2</sub> 897.2740, found 897.2751.</p></sec><sec id="Sec32"><title>Preparation of <italic toggle="yes">N</italic>-hydroxy-4-(((1-tosyl-1<italic toggle="yes">H</italic>-indol-3-yl)methyl)amino)benzamide (<bold>2d</bold>)</title><p id="Par71">Compound <bold>2d</bold> was synthesized from <bold>1d</bold> (0.20&#160;g, 0.45 mmol, 1.0 equiv.), hydroxylamine (50 wt % in water, 0.88 mL, 0.44&#160;g, 13.37 mmol, 30 equiv.) and sodium hydroxide (0.09&#160;g, 2.25 mmol, 5.0 equiv.) following the general procedure and reaction conditions described above. The crude product was purified by using silica gel with an eluent system of dichloromethane: methanol (94:6) to yield <bold>2d</bold> as light-pink crystals (CH<sub>2</sub>Cl<sub>2</sub>:MeOH(94:6)). The yield was 34% (66&#160;mg, 0.15 mmol), m.<italic toggle="yes">p</italic>&#8201;=&#8201;183&#8211;184&#160;&#176;C, R<sub>f</sub> = 0.32 (CH<sub>2</sub>Cl<sub>2</sub>:MeOH(94:6)). <sup>1</sup>H-NMR (400&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948; 2.29(s, 3&#160;H, Ar-<italic toggle="yes">CH</italic><sub><italic toggle="yes">3</italic></sub>), 4.43(d, <italic toggle="yes">J</italic>&#8201;=&#8201;5.6&#160;Hz, 2&#160;H, -N<italic toggle="yes">CH</italic><sub><italic toggle="yes">2</italic></sub>), 6.65(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4&#160;Hz, 2&#160;H, H-15), 6.71(t, <italic toggle="yes">J</italic>&#8201;=&#8201;6.2&#160;Hz, 1H, -N<italic toggle="yes">H-</italic>CH<sub>2</sub>), 7.26(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.5&#160;Hz, 1H, H-7), 7.33(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.2&#160;Hz, 2&#160;H, H-12), 7.33(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.2&#160;Hz, 1H, H-6), 7.53(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.3&#160;Hz, 2&#160;H, H-16), 7.72(d, <italic toggle="yes">J</italic>&#8201;=&#8201;7.5&#160;Hz, 1H, H-8), 7.75(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.3&#160;Hz, 2&#160;H, H-11), 7.77(s, 1H, H-2), 7.91(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.2&#160;Hz, 1H, H-5), 8.72(brs, 1H, -((CO)N<italic toggle="yes">H</italic>), 10.81(brs, 1H, -O<italic toggle="yes">H</italic>). <sup>13</sup>C-NMR (101&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948; 21.5( Ar-<italic toggle="yes">C</italic>H<sub>3</sub>), 38.2(N-<italic toggle="yes">C</italic>H<sub>2</sub>), 111.9(C-15), 113.8(C-5), 120.00(C-17), 120.9(C-8), 121.2(C-3), 123.8(C-7), 125.1(C-2), 125.4(C-6), 127.0(C-11), 128.6(C-16), 130.3(C-4), 130.60(C-12), 134.4 (C-10), 135.2(C-9), 145.8(C-13), 151.3(C-14). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> [M&#8201;+&#8201;Na]<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>NaO<sub>4</sub>S 458.1151, found 458.1156. [2&#160;M&#8201;+&#8201;H]<sup>+</sup> calcd. for C<sub>46</sub>H<sub>43</sub>N<sub>6</sub>O<sub>8</sub>S<sub>2</sub> 871.2584, found 871.2610.</p></sec><sec id="Sec33"><title>Preparation of <italic toggle="yes">N</italic>-hydroxy-4-(4-((1-tosyl-1<italic toggle="yes">H</italic>-indol-3-yl)methyl)piperazin-1-yl)benzamide (<bold>2e</bold>)</title><p id="Par73">Compound <bold>2e</bold> was synthesized from <bold>1e</bold> (0.15&#160;g, 0.29 mmol, 1 equiv.), hydroxylamine (50 wt % in water, 0.57 mL, 0.287&#160;g, 8.7 mmol, 30 equiv.) and sodium hydroxide (0.058&#160;g, 1.45 mmol, 5.0 equiv.) following the general procedure and reaction conditions described above. The crude product was purified by using silica gel with an eluent system of dichloromethane: methanol (90:10) to yield <bold>2e</bold> as light-pink crystals. The yield was 53% (77&#160;mg, 0.15 mmol), m.<italic toggle="yes">p</italic>&#8201;=&#8201;180&#8211;182&#160;&#176;C, R<sub>f</sub> = 0.43 (CH<sub>2</sub>Cl<sub>2</sub>:MeOH(90:10)). <sup>1</sup>H-NMR (400&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948; 2.26(s, 3&#160;H, Ar-<italic toggle="yes">CH</italic><sub><italic toggle="yes">3</italic></sub>), 2.49(t, <italic toggle="yes">J</italic>&#8201;=&#8201;8.2&#160;Hz, 4&#160;H, H-14), 3.20(t, <italic toggle="yes">J</italic>&#8201;=&#8201;4.8&#160;Hz, 4&#160;H, H-15), 3.65(s, 2&#160;H, H-C<italic toggle="yes">H</italic><sub>2</sub>N), 6.91(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.5&#160;Hz, 2&#160;H, H-17), 7.25(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.4&#160;Hz, 1H, H-7), 7.33(d, <italic toggle="yes">J</italic>&#8201;=&#8201;7.9&#160;Hz, 2&#160;H, H-12), 7.33(t <italic toggle="yes">J</italic>&#8201;=&#8201;7.6&#160;Hz, 1H, H-6), 7.68(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.3&#160;Hz, 2&#160;H, H-18), 7.72(s, 1H, H-2), 7.73(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.9&#160;Hz, 1H, H-8), 7.84(d, <italic toggle="yes">J</italic>&#8201;=&#8201;7.8&#160;Hz, 2&#160;H, H-11), 7.94(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.2&#160;Hz, 1H, H-5), 8.86(brs, 1H, -N<italic toggle="yes">H</italic>), 10.97(brs, 1H, -O<italic toggle="yes">H</italic>). <sup>13</sup>C-NMR (101&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948; 21.4( Ar-<italic toggle="yes">C</italic>H<sub>3</sub>), 47.6(C-15), 52.7(C-<italic toggle="yes">C</italic>H<sub>2</sub>N,14), 113.7(C-5), 114.2(C-17), 119.8(C-19), 121.2(C-8), 122.2(C-3), 123.8(C-7), 125.3(C-2), 125.7(C-6), 127.1(C-11), 128.6(C-18), 130.6(C-12), 131.1(C-4), 135.2(C-10), 135.6(C-9), 145.8(C-13), 153.2(C-16), 164.8(C&#8201;=&#8201;O). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>. [M-H<sup>+</sup>]<sup>+</sup> calcd for C<sub>27</sub>H<sub>27</sub>N<sub>4</sub>O<sub>4</sub>S<sup>&#8722;</sup> 503.1758, found 503.1766.</p></sec><sec id="Sec34"><title>Preparation of <italic toggle="yes">N</italic>-hydroxy-4-((quinolin-3-ylmethyl)amino)benzamide (<bold>2f</bold>)</title><p id="Par75">Compound <bold>2f</bold> was synthesized from <bold>1f</bold> (0.10&#160;g, 0.32 mmol, 1 equiv.), hydroxylamine (50 wt % in water, 0.63 mL, 0.32&#160;g, 9.60 mmol, 30 equiv.) and sodium hydroxide (0.05&#160;g, 1.28 mmol, 4.0 equiv.) following the general procedure and reaction conditions described above. The crude product was purified by soaking with dichloromethane to afford <bold>2f</bold> as white crystals. The yield was 53% (49&#160;mg, 0.17 mmol), m.<italic toggle="yes">p</italic>&#8201;=&#8201;201&#8211;203&#160;&#176;C. <sup>1</sup>H- NMR (400&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948; 4.56(d, <italic toggle="yes">J</italic>&#8201;=&#8201;6.0&#160;Hz, 2&#160;H, -N<italic toggle="yes">CH</italic><sub><italic toggle="yes">2</italic></sub>), 6.65(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4&#160;Hz, 2&#160;H, H-12), 6.94(t, <italic toggle="yes">J</italic>&#8201;=&#8201;6.0&#160;Hz, 1H, -N<italic toggle="yes">H-</italic>CH<sub>2</sub>), 7.53(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4&#160;Hz, 2&#160;H, H-13), 7.59(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.5&#160;Hz, 1H, H-7), 7.73(t, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4&#160;Hz, 1H, H-8), 7.94(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.1&#160;Hz, 1H, H-6), 8.01(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.4&#160;Hz, 1H, H-9), 8.25(d, <italic toggle="yes">J</italic>&#8201;=&#8201;2.2&#160;Hz, 1H, H-4), 8.69(brs, 1H, -N<italic toggle="yes">H</italic>), 8.93(d, <italic toggle="yes">J</italic>&#8201;=&#8201;2.2&#160;Hz, 1H, H-2), 10.77(s, 1H, -O<italic toggle="yes">H</italic>). <sup>13</sup>C-NMR (101&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948; 44.4(-N<italic toggle="yes">C</italic>H<sub>2</sub>), 111.9(C-12), 120.3(C-14), 127.3(C-7), 128.0(C-5), 128.3(C-6), 128.8(C-13), 129.2(C-9), 129.6(C-8), 133.1(C-3), 133.9(C-4), 147.3(C-10), 151.2(C-11), 151.4(C-2), 165.4(C&#8201;=&#8201;O). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> [M-H]<sup>+</sup> calcd. for C<sub>17</sub>H<sub>14</sub>N<sub>3</sub>O<sub>2</sub> 292.1086, found 292.1084.</p></sec><sec id="Sec35"><title>Preparation of <italic toggle="yes">N</italic>-hydroxy-4-{4-[(quinolin-3-yl)methyl]piperazin-1-yl}benzamide (<bold>2g</bold>)</title><p id="Par77">Compound <bold>2g</bold> was synthesized from <bold>1g</bold> (0.10&#160;g, 0.27 mmol, 1 equiv.), hydroxylamine (50 wt % in water, 0.52 mL, 0.26&#160;g, 7.99 mmol, 30 equiv.) and sodium hydroxide (0.04&#160;g, 1.08 mmol, 4.0 equiv) following the general procedure and reaction conditions described above. The crude product was purified by soaking with dichloromethane to afford <bold>2g</bold> as white crystals. The yield was 73% (71&#160;mg, 0.20 mmol), m.<italic toggle="yes">p</italic>&#8201;=&#8201;215&#8211;216&#160;&#176;C. <sup>1</sup>H-NMR (400&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948;&#8201;=&#8201;2.55(s, 4&#160;H, H-11), 3.26(s, 4&#160;H, H-12), 3.74(s, 2&#160;H, H-C<italic toggle="yes">H</italic><sub>2</sub>N), 6.93(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.6&#160;Hz, 2&#160;H, H-14), 7.62(t, <italic toggle="yes">J</italic>&#8201;=&#8201;7.3&#160;Hz, 1H, H-7), 7.64(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.3&#160;Hz, 2&#160;H, H-15), 7.76(t <italic toggle="yes">J</italic>&#8201;=&#8201;6.6&#160;Hz, 1H, H-8), 7.99(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.3&#160;Hz, 1H, H-6), 8.03(d, <italic toggle="yes">J</italic>&#8201;=&#8201;8.3&#160;Hz, 1H, H-9), 8.26(s, 1H, H-4), 8.84(brs, 1H, -N<italic toggle="yes">H</italic>), 8.90(s, 1H, H-2), 10.96(s, 1H, -O<italic toggle="yes">H</italic>). <sup>13</sup>C-NMR (101&#160;MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>, TMS) &#948; 47.6(C-12), 52.8(C-11), 59.8(N<italic toggle="yes">C</italic>H<sub>2</sub>), 114.2(C-14), 122.4(C-16), 127.2(C-7), 127.9(C-5), 128.4(C-6), 128.5(C-9), 129.2(C-8), 129.6(C-15), 131.4(C-3), 135.8(C-4), 147.4(C-10), 152.5(C-2), 153.2(C-13). HRMS <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> [M&#8201;+&#8201;2&#160;H]<sup>+</sup> calcd. for C<sub>21</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>: 364.1888, found: 364.1885.</p></sec></sec></sec><sec id="Sec16"><title>Pharmacological/biological assays</title><sec id="Sec36"><title>The cytotoxic activity</title><p id="Par79">The cytotoxic activity of all pure compounds was determined towards a panel of four human solid tumour cell lines: melanoma (SK-MEL), epidermal carcinoma (KB), breast carcinoma (BT-549), and ovarian carcinoma (SK-OV-3). Moreover, non-cancer kidney cell lines (LLC-PK1 and VERO) were also employed to determine if the anti-cell proliferative activity of these compounds was selective for the tested tumour cell lines. All cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The cells were seeded in 96-well plates (10,000 cells/well) and incubated for 24&#160;h. All ligands were dissolved in DMSO, diluted in media, and added to the cells at concentrations of 80, 40, 20, and 10 &#181;M. After incubating for 48&#160;h, cell viability was determined using a tetrazolium dye WST-8, which is converted to a water-soluble formazan product in the presence of 1-methoxy PMS by the activity of cellular enzymes. The colour of the formazan product was measured at 450&#160;nm on a plate reader. Doxorubicin was used as a positive control for the cytotoxicity assay, and DMSO (0.25%) was used as the vehicle control. The IC<sub>50</sub> values were obtained from concentration-response curves. The values are represented as mean&#8201;&#177;&#8201;standard deviation (<italic toggle="yes">n</italic>&#8201;=&#8201;3).</p></sec><sec id="Sec37"><title>Enzymatic in vitro HDAC inhibitory activity</title><p id="Par81">Recombinant human HDAC1, HDAC2, HDAC3/NCOR1, and HDAC6 were purchased from ENZO Life Sciences AG (Lausen, CH). Barinka et al.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> produced recombinant drHDAC10 wild type. Recombinant human HDAC8 was produced by Romier et al.<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. In vitro testing of the inhibitors in an enzymatic assay was carried out as described in previous publications by us<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR43">43</xref>&#8211;<xref ref-type="bibr" rid="CR46">46</xref></sup>. Inhibitory activity for HDAC1, HDAC2, HDAC3, and HDAC6 was determined using a discontinuous assay with a substrate peptide derived from p53 (Ac-RHKK(Ac)-AMC) in a 384 well-plate. The enzyme at final concentrations (10 nM HDAC1, 3 nM HDAC2 and HDAC3, and 1 nM HDAC6,) and the inhibitors at various concentrations were incubated for 5&#160;min in assay buffer (50 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 1 mM TCEP and 0.2&#160;mg/mL BSA, pH 7.4 adjusted with NaOH). The reaction started with the addition of substrate (20 &#181;M HDAC1-3 and 5 &#181;M HDAC6). Afterwards, the fluorescence was developed with a 0.5&#160;mg/mL trypsin solution (final concentration), and the fluorescence readout was done with an Envision 2104 Multilabel Plate Reader (PerkinElmer, Waltham, USA) with &#955;<sub>Ex</sub>&#8201;=&#8201;380&#8201;&#177;&#8201;10&#160;nm and &#955;<sub>Em</sub>&#8201;=&#8201;430&#8201;&#177;&#8201;8&#160;nm.</p><p id="Par82">For HDAC8 the fluorogenic peptide derivate Abz-SRGGK(thio-TFA)FFRR-NH2 was applied as described in<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. For HDAC10 a spermidine derivative Ac-spermidine-AMC was applied. The HDAC8 assay was performed in the same assay buffer as described above. For HDAC10 the assay buffer was 20 mM HEPES, pH 7.4, and 0.5&#160;mg/mL BSA. The enzyme (1.5 nM HDAC8 or 5 nM HDAC10 final concentration) was incubated for 5&#160;min with various concentrations of the inhibitor. The reaction was started with the addition of 50 &#181;M substrate and the readout was done continuously with an Envision 2104 with &#955;<sub>Ex</sub>&#8201;=&#8201;330&#8201;&#177;&#8201;75&#160;nm, and &#955;<sub>Em</sub>&#8201;=&#8201;430&#8201;&#177;&#8201;8&#160;nm.</p><p id="Par83">For HDAC1, 2, and 3 a fluorogenic peptide derived from p53 (Ac-RHKK(Acetyl)-AMC) was applied. The measurements were performed in assay buffer (50 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 1 mM TCEP, and 0.2&#160;mg/mL BSA, pH 7.4 adjusted with NaOH) at 37&#160;&#176;C. An Envision 2104 Multilabel Plate Reader (PerkinElmer, Waltham, MA), with an excitation wavelength of 380&#8201;&#177;&#8201;8&#160;nm and an emission wavelength of 430&#8201;&#177;&#8201;8&#160;nm was considered to measure the fluorescence intensity. For HDAC6 the substrate (Abz-SRGGK(thio-TFA)FFRR-NH2) was applied as described before<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. The HDAC10 inhibition assay was performed as described before<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> using Ac-spermidine-AMC as substrate. The idea of this discontinuous assay is the HDAC10 mediated generation of a primary amino function. The released primary amine is reacted wirh 2,3-Naphthalenedicarboxaldehyde (NDA) resulting in an NDA-spermidin-AMC derivative which differences in the AMC fluorescence intensities as compared to Ac-spermidin AMC. The assay was performed in black 96-well plates (PerkinElmer, OptiPlateTM-96&#160;F). The compounds to be tested were incubated for 25&#160;min at 25&#160;&#176;C. Before measuring fluorescence (POLARstar plate reader, &#955;ex&#8201;=&#8201;330&#160;nm, &#955;em&#8201;=&#8201;390&#160;nm) each well was filled with 200 &#181;L stop solution containing 16mM NDA). (for assay details please refer to<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. The enzyme inhibition of HDAC8 was determined by using a homogenous fluorescence assay<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. The enzyme was incubated for 90&#160;min at 37&#160;&#176;C, with the fluorogenic substrate ZMAL (Z(Ac)Lys-AMC) in a concentration of 10.5 &#181;M and increasing concentrations of inhibitors. Fluorescence intensity was measured at an excitation wavelength of 390&#160;nm and an emission wavelength of 460&#160;nm in a microtiter plate reader (BMG Polarstar).</p></sec></sec><sec id="Sec17"><title>Molecular docking</title><sec id="Sec38"><title>Molecular docking</title><p id="Par85">Available crystal structures of drHDAC10, hsHDAC1, hsHDAC6 and hsHDAC8 were downloaded (PDB ID: 6UHU, PDB ID: 5ICN, PDB ID: 5EDU, and PDB ID: 2V5X respectively) from the Protein Data Bank (PDB;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.rscb.org">www.rscb.org</ext-link>)<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. All ligands and all protein-ligand complexes were prepared using similar methods as published before<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. Validation of the molecular docking method was performed by re-docking the ligands co-crystallized in HDAC10 as reported in our previous publication<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. For the preparation of the proteins, the wizard implementation of the Schr&#246;dinger version 2019.1 was used with the following steps: hydrogen atoms addition, protonation states assignment, and finally, restrained energy minimization using the OPLS force field 2005. The ligand structure was generated using the 2D Sketcher of Schr&#246;dinger (version 2019.1). Afterward, the LigPrep tool (Schr&#246;dinger version 2019.1) was used for the preparation of the ligands with energy minimization using the OPLS2005 force field<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup>. 64 conformers for each ligand were generated with the ConfGen tool (Schr&#246;dinger version 2019.1). Preparation of the receptor grid for the docking procedure was performed by assigning the co-crystallized ligands as the centroid of the grid box in each PDB crystal structure using the receptor grid preparation module in Schr&#246;dinger (version 2019.1). Lastly, docking of all generated conformers was done in the Standard Precision mode using the Glide (Schr&#246;dinger-release 2019.1).</p></sec><sec id="Sec39"><title>Molecular dynamics (MD) simulations</title><p id="Par87">AMBER22 was used to perform GPU-based MD simulations. PDB4Amber command was used for the preparation of the protein structures for further usage within the tLEaP program. Topology and force field parameters of the ligands were assigned with Antechamber<sup><xref ref-type="bibr" rid="CR50">50</xref></sup> package using the second generation general Amber force field (GAFF2) and the semi-empirical AM1-BCC (Austin Model1 with bond charge correction) as atomic charge method<sup><xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup>. Afterwards, the protein-ligand complexes were created with the AMBER22 tLEaP module. The second-generation general AMBER force field (GAFF2) was used as the ligand force field while force field 14 Stony Brook-ff14SB was used for the protein structures<sup><xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR54">54</xref></sup>. For the catalytic Zn2+, the 12-6-4 LJ-type nonbonded ion model was applied<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. After combining the protein and the ligands, complexes were solvated by transferable intermolecular potential 3P-TIP3P water model as an octahedral box around the protein with a 10 &#197; margin. Then Na&#8201;+&#8201;and Cl- ions were added to neutralize the whole system. Parameter/topology files of the entire system were created with tLEaP and the files were used as a starting point for the MD simulations. The solvated systems were first subjected to two energy minimization steps involving 1000 cycles of steepest descent followed by 2000 cycles of conjugate gradient totaling 3000 cycles of minimization. In the first energy minimization step, only the solvent molecules and counter-ions (Na&#8201;+&#8201;and Cl-) were minimized while applying constraints with a force constant of 10&#160;kcal*mol-1*&#197;-2 to the proteins, ligands, and zinc ion. In the second minimization step, the whole system was minimized without constraints. Subsequently, the systems were heated from 0 to 300&#160;K over 100 ps while applying the same constraints on the solute as in minimization step1. Constant volume periodic boundary was set to equilibrate the temperature of the system by Langevin thermostat using a collision frequency of 2 ps-1. Subsequently, a pressure equilibration routine with a constant pressure of 1&#160;bar and at 300&#160;K was performed for 100 ps. Finally, 100 ns free molecular dynamic simulations with the time step of 2&#160;fs were applied utilizing the Particle Mesh Ewald method<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. The system temperature was kept at 300&#160;K with a Langevin thermostat using 2 ps-1 collision frequency and the pressure of the system was maintained at 1&#160;bar with the usage of isotropic position scaling and a relaxation time of 2 ps. Implementation of the SHAKE algorithm was done to constrain all bonds containing hydrogens. A total of 1000 frames were written for 100 ns long MDs. Simulations of the prepared crystal structures of humanized drHDAC10 (PDB IDs; 7U6B, 7U69, 7U6A, 7U69) X-ray structures and the docking pose of ligand 1 in drHDAC10 (PDB ID:6UHU) were repeated three times from the minimization steps with non-identical random seeds. The analysis of the MD trajectories was performed using the CPPTRAJ module in AMBER 22. The RMSD of the protein was calculated for the backbone atoms using CPPTRAJ. RMSF of the ligand as well as distances between the hydroxamate group oxygens and the zinc ion were calculated to further examine the stability of the protein-ligand complexes using CPPTRAJ. Additionally, the obtained trajectories were clustered based on the ligand-heavy atoms using the K-means algorithm and pytraj implementation of AMBER.</p></sec><sec id="Sec40"><title>PAINS filter</title><p id="Par89">Inhibitors described herein were filtered for pan-assay interference compounds (PAINS). For this purpose, PAINS1, PAINS2, and PAINS3 filters, as implemented in Schroedinger&#8217;s Canvas program (Schr&#246;dinger version 2019.1), were employed. None of the compounds was flagged as PAINS.</p></sec></sec></sec><sec id="Sec18" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_2774_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to express our appreciation to Dr. Shabana Khan for overseeing the biological assay. Dr. Khan evaluated the cytotoxicity of the synthesized ligands across various cell lines. This work was funded in part by the Deutsche Forschungsgemeinschaft (DFG) SI868/22&#8201;&#8722;&#8201;1, project number 46995445 (to W.S.).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization, A.T., W.S., S.R. and S.A.; methodology, A.T., W.S. and S.R.; software, M.S.; validation, W.S., A.T., S.A. and S.R.,.; formal analysis, M.S., T.Y., M.Z., D.R. and C.B.; investigation, A.T, M.S., T.Y., M.Z., D.R. and C.B.; resources, S.R. and W.S.; data curation, A.T and W.S.; writing&#8212;original draft preparation, A.T.; writing&#8212;review and editing, S.A., M.S. and S.R.,; visualization, W.S and A.T.; supervision, A.T, W.S. and S.R.; project administration, A.T and W.S.; funding acquisition, S.R and W.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data is provided within the manuscript or supplementary information files.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par90">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>J</given-names></name><name name-style="western"><surname>Baeza</surname><given-names>J</given-names></name><name name-style="western"><surname>Denu</surname><given-names>JM</given-names></name></person-group><article-title>Investigating histone acetylation stoichiometry and turnover rate</article-title><source>Methods Enzymol.</source><year>2012</year><volume>574</volume><fpage>125</fpage><pub-id pub-id-type="doi">10.1016/bs.mie.2016.01.007</pub-id><pub-id pub-id-type="pmid">27423860</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Fan, J., Baeza, J. &amp; Denu, J. M. Investigating histone acetylation stoichiometry and turnover rate. <italic toggle="yes">Methods Enzymol.</italic><bold>574</bold>, 125. 10.1016/bs.mie.2016.01.007 (2016).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.mie.2016.01.007</pub-id><pub-id pub-id-type="pmid">27423860</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>O</given-names></name><name name-style="western"><surname>La Thangue</surname><given-names>NB</given-names></name></person-group><article-title>HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications</article-title><source>Immunol Cell. Biol.</source><year>2012</year><volume>90</volume><fpage>85</fpage><pub-id pub-id-type="doi">10.1038/icb.2011.100</pub-id><pub-id pub-id-type="pmid">22124371</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Khan, O. &amp; La Thangue, N. B. HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. <italic toggle="yes">Immunol Cell. Biol.</italic><bold>90</bold>, 85. 10.1038/icb.2011.100 (2012).<pub-id pub-id-type="pmid">22124371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/icb.2011.100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ceccacci</surname><given-names>E</given-names></name><name name-style="western"><surname>Minucci</surname><given-names>S</given-names></name></person-group><article-title>Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia</article-title><source>Br. J. Cancer</source><year>2016</year><volume>114</volume><fpage>605</fpage><pub-id pub-id-type="doi">10.1038/bjc.2016.36</pub-id><pub-id pub-id-type="pmid">26908329</pub-id><pub-id pub-id-type="pmcid">PMC4800301</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Ceccacci, E. &amp; Minucci, S. Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia. <italic toggle="yes">Br. J. Cancer</italic><bold>114</bold>, 605. 10.1038/bjc.2016.36 (2016).<pub-id pub-id-type="pmid">26908329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.2016.36</pub-id><pub-id pub-id-type="pmcid">PMC4800301</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>WG</given-names></name></person-group><article-title>The roles of histone deacetylases and their inhibitors in cancer therapy</article-title><source>Front. Cell. Dev. Biol.</source><year>2020</year><volume>8</volume><fpage>576946</fpage><pub-id pub-id-type="doi">10.3389/fcell.2020.576946</pub-id><pub-id pub-id-type="pmid">33117804</pub-id><pub-id pub-id-type="pmcid">PMC7552186</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Li, G., Tian, Y. &amp; Zhu, W. G. The roles of histone deacetylases and their inhibitors in cancer therapy. <italic toggle="yes">Front. Cell. Dev. Biol.</italic><bold>8</bold>, 576946. 10.3389/fcell.2020.576946 (2020).<pub-id pub-id-type="pmid">33117804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2020.576946</pub-id><pub-id pub-id-type="pmcid">PMC7552186</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>San Jos&#233;-En&#233;riz</surname><given-names>E</given-names></name><name name-style="western"><surname>Gimenez-Camino</surname><given-names>N</given-names></name><name name-style="western"><surname>Agirre</surname><given-names>X</given-names></name><name name-style="western"><surname>Prosper</surname><given-names>F</given-names></name></person-group><article-title>HDAC inhibitors in acute myeloid leukemia</article-title><source>Cancers</source><year>2019</year><volume>11</volume><fpage>1794</fpage><pub-id pub-id-type="doi">10.3390/cancers11111794</pub-id><pub-id pub-id-type="pmid">31739588</pub-id><pub-id pub-id-type="pmcid">PMC6896008</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">San Jos&#233;-En&#233;riz, E., Gimenez-Camino, N., Agirre, X. &amp; Prosper, F. <italic toggle="yes">Cancers</italic><bold>11</bold>, 1794. 10.3390/cancers11111794 (2019).<pub-id pub-id-type="pmid">31739588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11111794</pub-id><pub-id pub-id-type="pmcid">PMC6896008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kr&#228;mer</surname><given-names>OH</given-names></name></person-group><article-title>HDAC2: A critical factor in health and disease</article-title><source>Trends Pharmacol. Sci.</source><year>2009</year><volume>30</volume><fpage>647</fpage><pub-id pub-id-type="doi">10.1016/j.tips.2009.09.007</pub-id><pub-id pub-id-type="pmid">19892411</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Kr&#228;mer, O. H. HDAC2: A critical factor in health and disease. <italic toggle="yes">Trends Pharmacol. Sci.</italic><bold>30</bold>, 647. 10.1016/j.tips.2009.09.007 (2009).<pub-id pub-id-type="pmid">19892411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2009.09.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Design, synthesis, and pharmacological evaluation of novel <italic toggle="yes">N</italic>-acylhydrazone derivatives as potent histone deacetylase 6/8 dual inhibitors</article-title><source>J. Med. Chem.</source><year>2016</year><volume>59</volume><fpage>655</fpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01525</pub-id><pub-id pub-id-type="pmid">26705137</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Rodrigues, D. A. et al. Design, synthesis, and pharmacological evaluation of novel <italic toggle="yes">N</italic>-acylhydrazone derivatives as potent histone deacetylase 6/8 dual inhibitors. <italic toggle="yes">J. Med. Chem.</italic><bold>59</bold>, 655. 10.1021/acs.jmedchem.5b01525 (2016).<pub-id pub-id-type="pmid">26705137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.5b01525</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shinsky</surname><given-names>SA</given-names></name><name name-style="western"><surname>Porter</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Christianson</surname><given-names>DW</given-names></name></person-group><article-title>Histone deacetylase 10 structure and molecular function as a polyamine deacetylase</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>15368</fpage><pub-id pub-id-type="doi">10.1038/ncomms15368</pub-id><pub-id pub-id-type="pmid">28516954</pub-id><pub-id pub-id-type="pmcid">PMC5454378</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Hai, Y., Shinsky, S. A., Porter, N. J. &amp; Christianson, D. W. Histone deacetylase 10 structure and molecular function as a polyamine deacetylase. <italic toggle="yes">Nat. Commun.</italic><bold>8</bold>, 15368. 10.1038/ncomms15368 (2017).<pub-id pub-id-type="pmid">28516954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms15368</pub-id><pub-id pub-id-type="pmcid">PMC5454378</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oehme</surname><given-names>I</given-names></name><etal/></person-group><article-title>Histone deacetylase 10 promotes autophagy-mediated cell survival</article-title><source>Proc. Natl. Acad. Sci. U. S. A</source><year>2013</year><volume>110</volume><fpage>E2592</fpage><pub-id pub-id-type="doi">10.1073/pnas.1300113110</pub-id><pub-id pub-id-type="pmid">23801752</pub-id><pub-id pub-id-type="pmcid">PMC3710791</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Oehme, I. et al. Histone deacetylase 10 promotes autophagy-mediated cell survival. <italic toggle="yes">Proc. Natl. Acad. Sci. U. S. A</italic><bold>110</bold>, E2592 (2013). 10.1073/pnas.1300113110<pub-id pub-id-type="pmid">23801752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1300113110</pub-id><pub-id pub-id-type="pmcid">PMC3710791</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinsky</surname><given-names>SA</given-names></name><name name-style="western"><surname>Christianson</surname><given-names>DW</given-names></name></person-group><article-title>Polyamine deacetylase structure and catalysis: Prokaryotic acetylpolyamine amidohydrolase and eukaryotic HDAC10</article-title><source>Biochemistry</source><year>2018</year><volume>57</volume><fpage>3105</fpage><pub-id pub-id-type="doi">10.1021/acs.biochem.8b00079</pub-id><pub-id pub-id-type="pmid">29533602</pub-id><pub-id pub-id-type="pmcid">PMC5988950</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Shinsky, S. A. &amp; Christianson, D. W. Polyamine deacetylase structure and catalysis: Prokaryotic acetylpolyamine amidohydrolase and eukaryotic HDAC10. <italic toggle="yes">Biochemistry</italic><bold>57</bold>, 3105 (2018). 10.1021/acs.biochem.8b00079<pub-id pub-id-type="pmid">29533602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.biochem.8b00079</pub-id><pub-id pub-id-type="pmcid">PMC5988950</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group><article-title>The interplay between DNA repair and autophagy in cancer therapy</article-title><source>Cancer Biol. Ther.</source><year>2015</year><volume>16</volume><fpage>1005</fpage><pub-id pub-id-type="doi">10.1080/15384047.2015.1046022</pub-id><pub-id pub-id-type="pmid">25985143</pub-id><pub-id pub-id-type="pmcid">PMC4622693</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Zhang, D. et al. The interplay between DNA repair and autophagy in cancer therapy. <italic toggle="yes">Cancer Biol. Ther.</italic><bold>16</bold>, 1005. 10.1080/15384047.2015.1046022 (2015).<pub-id pub-id-type="pmid">25985143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15384047.2015.1046022</pub-id><pub-id pub-id-type="pmcid">PMC4622693</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumagai</surname><given-names>T</given-names></name><etal/></person-group><article-title>Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells</article-title><source>Int. J. Cancer</source><year>2007</year><volume>121</volume><fpage>656</fpage><pub-id pub-id-type="doi">10.1002/ijc.22558</pub-id><pub-id pub-id-type="pmid">17417771</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Kumagai, T. et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. <italic toggle="yes">Int. J. Cancer</italic><bold>121</bold>, 656. 10.1002/ijc.22558 (2007).<pub-id pub-id-type="pmid">17417771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.22558</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raphael</surname><given-names>S</given-names></name><etal/></person-group><article-title>Aza-SAHA derivatives are selective histone deacetylase 10 chemical probes that inhibit polyamine deacetylation and phenocopy HDAC10 knockout</article-title><source>J. Am. Chem. Soc.</source><year>2022</year><volume>41</volume><fpage>18861</fpage><pub-id pub-id-type="doi">10.1021/jacs.2c05030</pub-id><pub-id pub-id-type="pmcid">PMC9588710</pub-id><pub-id pub-id-type="pmid">36200994</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Raphael, S. et al. Aza-SAHA derivatives are selective histone deacetylase 10 chemical probes that inhibit polyamine deacetylation and phenocopy HDAC10 knockout. <italic toggle="yes">J. Am. Chem. Soc.</italic><bold>41</bold>, 18861. 10.1021/jacs.2c05030 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.2c05030</pub-id><pub-id pub-id-type="pmcid">PMC9588710</pub-id><pub-id pub-id-type="pmid">36200994</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>X</given-names></name><etal/></person-group><article-title>Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer</article-title><source>Int. J. Cancer</source><year>2008</year><volume>122</volume><fpage>1400</fpage><pub-id pub-id-type="doi">10.1002/ijc.23243</pub-id><pub-id pub-id-type="pmid">18027850</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Qian, X. et al. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. <italic toggle="yes">Int. J. Cancer</italic><bold>122</bold>, 1400. 10.1002/ijc.23243 (2008).<pub-id pub-id-type="pmid">18027850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.23243</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piekarz</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma</article-title><source>J. Clin. Oncol.</source><year>2009</year><volume>27</volume><fpage>5410</fpage><pub-id pub-id-type="doi">10.1200/JCO.2008.21.6150</pub-id><pub-id pub-id-type="pmid">19826128</pub-id><pub-id pub-id-type="pmcid">PMC2773225</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Piekarz, R. L. et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. <italic toggle="yes">J. Clin. Oncol.</italic><bold>27</bold>, 5410. 10.1200/JCO.2008.21.6150 (2009).<pub-id pub-id-type="pmid">19826128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2008.21.6150</pub-id><pub-id pub-id-type="pmcid">PMC2773225</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellis</surname><given-names>L</given-names></name><etal/></person-group><article-title>Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>4500</fpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4262</pub-id><pub-id pub-id-type="pmid">18628465</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Ellis, L. et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. <italic toggle="yes">Clin. Cancer Res.</italic><bold>14</bold>, 4500. 10.1158/1078-0432.CCR-07-4262 (2008).<pub-id pub-id-type="pmid">18628465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-07-4262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Synthesis and biological evaluation of ortho&#8208;aryl N&#8208;hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform&#8208;selective inhibitors</article-title><source>ChemMedChem</source><year>2012</year><volume>7</volume><fpage>1815</fpage><pub-id pub-id-type="doi">10.1002/cmdc.201200300</pub-id><pub-id pub-id-type="pmid">22907916</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Huang, W. J. et al. Synthesis and biological evaluation of ortho&#8208;aryl N&#8208;hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform&#8208;selective inhibitors. <italic toggle="yes">ChemMedChem</italic><bold>7</bold>, 1815. 10.1002/cmdc.201200300 (2012).<pub-id pub-id-type="pmid">22907916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cmdc.201200300</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>N</given-names></name><etal/></person-group><article-title>Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors</article-title><source>Biochem. J.</source><year>2008</year><volume>409</volume><fpage>581</fpage><pub-id pub-id-type="doi">10.1042/BJ20070779</pub-id><pub-id pub-id-type="pmid">17868033</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Khan, N. et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. <italic toggle="yes">Biochem. J.</italic><bold>409</bold>, 581. 10.1042/BJ20070779 (2008).<pub-id pub-id-type="pmid">17868033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BJ20070779</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Li, Y. &amp; Seto, E. HDACs and HDAC inhibitors in cancer development and therapy. <italic toggle="yes">Cold Spring Harb Perspect. Med.</italic><bold>6</bold>. 10.1101/cshperspect.a026831 (2016).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a026831</pub-id><pub-id pub-id-type="pmcid">PMC5046688</pub-id><pub-id pub-id-type="pmid">27599530</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H</given-names></name><name name-style="western"><surname>He</surname><given-names>YW</given-names></name></person-group><article-title>Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals</article-title><source>Biol. Chem.</source><year>2016</year><volume>397</volume><fpage>75</fpage><pub-id pub-id-type="doi">10.1515/hsz-2015-0215</pub-id><pub-id pub-id-type="pmid">26431101</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Wu, S., Luo, Z., Yu, P. J., Xie, H. &amp; He, Y. W. Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals. <italic toggle="yes">Biol. Chem.</italic><bold>397</bold>, 75. 10.1515/hsz-2015-0215 (2016).<pub-id pub-id-type="pmid">26431101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/hsz-2015-0215</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlisi</surname><given-names>D</given-names></name><etal/></person-group><article-title>The synergistic effect of SAHA and parthenolide in MDA&#8208;MB231 breast cancer cells</article-title><source>J. Cell. Physiol.</source><year>2015</year><volume>230</volume><fpage>1276</fpage><pub-id pub-id-type="doi">10.1002/jcp.24863</pub-id><pub-id pub-id-type="pmid">25370819</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Carlisi, D. et al. The synergistic effect of SAHA and parthenolide in MDA&#8208;MB231 breast cancer cells. <italic toggle="yes">J. Cell. Physiol.</italic><bold>230</bold>, 1276. 10.1002/jcp.24863 (2015).<pub-id pub-id-type="pmid">25370819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.24863</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiu</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e76340</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0076340</pub-id><pub-id pub-id-type="pmid">24130769</pub-id><pub-id pub-id-type="pmcid">PMC3794942</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Chiu, H. W. et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. <italic toggle="yes">PLoS One</italic><bold>8</bold>, e76340. 10.1371/journal.pone.0076340 (2013).<pub-id pub-id-type="pmid">24130769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0076340</pub-id><pub-id pub-id-type="pmcid">PMC3794942</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ridinger</surname><given-names>J</given-names></name><etal/></person-group><article-title>Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>10039</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-28265-5</pub-id><pub-id pub-id-type="pmid">29968769</pub-id><pub-id pub-id-type="pmcid">PMC6030077</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Ridinger, J. et al. Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance. <italic toggle="yes">Sci. Rep.</italic><bold>8</bold>, 10039. 10.1038/s41598-018-28265-5 (2018).<pub-id pub-id-type="pmid">29968769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-28265-5</pub-id><pub-id pub-id-type="pmcid">PMC6030077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>YY</given-names></name><etal/></person-group><article-title>HDAC10 inhibits cervical cancer progression through downregulating the HDAC10&#8208;microRNA&#8208;223&#8208;EPB41L3 axis</article-title><source>J. Oncol.</source><year>2022</year><volume>1</volume><fpage>8092751</fpage><pub-id pub-id-type="doi">10.1155/2022/8092751</pub-id><pub-id pub-id-type="pmcid">PMC8783137</pub-id><pub-id pub-id-type="pmid">35075362</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Gu, Y. Y. et al. HDAC10 inhibits cervical cancer progression through downregulating the HDAC10&#8208;microRNA&#8208;223&#8208;EPB41L3 axis. <italic toggle="yes">J. Oncol.</italic><bold>1</bold>, 8092751. 10.1155/2022/8092751 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/8092751</pub-id><pub-id pub-id-type="pmcid">PMC8783137</pub-id><pub-id pub-id-type="pmid">35075362</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbst-Gervasoni</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Steimbach</surname><given-names>RR</given-names></name><name name-style="western"><surname>Morgen</surname><given-names>M</given-names></name><name name-style="western"><surname>Miller</surname><given-names>AK</given-names></name><name name-style="western"><surname>Christianson</surname><given-names>DW</given-names></name></person-group><article-title>Structural basis for the selective inhibition of HDAC10, the cytosolic polyamine deacetylase</article-title><source>ACS Chem. Biol.</source><year>2020</year><volume>15</volume><fpage>2154</fpage><pub-id pub-id-type="doi">10.1021/acschembio.0c00362</pub-id><pub-id pub-id-type="pmid">32659072</pub-id><pub-id pub-id-type="pmcid">PMC7442746</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Herbst-Gervasoni, C. J., Steimbach, R. R., Morgen, M., Miller, A. K. &amp; Christianson, D. W. Structural basis for the selective inhibition of HDAC10, the cytosolic polyamine deacetylase. <italic toggle="yes">ACS Chem. Biol.</italic><bold>15</bold>, 2154. 10.1021/acschembio.0c00362 (2020).<pub-id pub-id-type="pmid">32659072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschembio.0c00362</pub-id><pub-id pub-id-type="pmcid">PMC7442746</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#233;raldy</surname><given-names>M</given-names></name><etal/></person-group><article-title>Selective inhibition of histone deacetylase 10: Hydrogen bonding to the gatekeeper residue is implicated</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><fpage>4426</fpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01936</pub-id><pub-id pub-id-type="pmid">30964290</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">G&#233;raldy, M. et al. Selective inhibition of histone deacetylase 10: Hydrogen bonding to the gatekeeper residue is implicated. <italic toggle="yes">J. Med. Chem.</italic><bold>62</bold>, 4426. 10.1021/acs.jmedchem.8b01936 (2019).<pub-id pub-id-type="pmid">30964290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.8b01936</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolbinger</surname><given-names>FR</given-names></name><etal/></person-group><article-title>The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines</article-title><source>Arch. Toxicol.</source><year>2018</year><volume>92</volume><fpage>2649</fpage><pub-id pub-id-type="doi">10.1007/s00204-018-2234-8</pub-id><pub-id pub-id-type="pmid">29947893</pub-id><pub-id pub-id-type="pmcid">PMC6063332</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Kolbinger, F. R. et al. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines. <italic toggle="yes">Arch. Toxicol.</italic><bold>92</bold>, 2649. 10.1007/s00204-018-2234-8 (2018).<pub-id pub-id-type="pmid">29947893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00204-018-2234-8</pub-id><pub-id pub-id-type="pmcid">PMC6063332</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Woster</surname><given-names>PM</given-names></name></person-group><article-title>Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group</article-title><source>Medchemcomm</source><year>2015</year><volume>6</volume><fpage>613</fpage><pub-id pub-id-type="doi">10.1039/C4MD00401A</pub-id><pub-id pub-id-type="pmid">26005563</pub-id><pub-id pub-id-type="pmcid">PMC4440699</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Li, Y. &amp; Woster, P. M. Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group. <italic toggle="yes">Medchemcomm</italic><bold>6</bold>, 613 (2015). 10.1039/C4MD00401A<pub-id pub-id-type="pmid">26005563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/C4MD00401A</pub-id><pub-id pub-id-type="pmcid">PMC4440699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herp</surname><given-names>D</given-names></name><etal/></person-group><article-title>First fluorescent acetylspermidine deacetylation assay for HDAC10 identifies selective inhibitors with cellular target engagement</article-title><source>Chembiochem</source><year>2022</year><volume>23</volume><fpage>e202200180</fpage><pub-id pub-id-type="doi">10.1002/cbic.202200180</pub-id><pub-id pub-id-type="pmid">35608330</pub-id><pub-id pub-id-type="pmcid">PMC9308754</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Herp, D. et al. First fluorescent acetylspermidine deacetylation assay for HDAC10 identifies selective inhibitors with cellular target engagement. <italic toggle="yes">Chembiochem</italic><bold>23</bold>, e202200180. 10.1002/cbic.202200180 (2022).<pub-id pub-id-type="pmid">35608330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cbic.202200180</pub-id><pub-id pub-id-type="pmcid">PMC9308754</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeyen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells</article-title><source>Eur. J. Med. Chem.</source><year>2022</year><volume>234</volume><fpage>114272</fpage><pub-id pub-id-type="doi">10.1002/cbic.202200180</pub-id><pub-id pub-id-type="pmid">35306288</pub-id><pub-id pub-id-type="pmcid">PMC9007901</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Zeyen, P. et al. Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells. <italic toggle="yes">Eur. J. Med. Chem.</italic><bold>234</bold>, 114272. 10.1016/j.ejmech.2022.114272 (2022).<pub-id pub-id-type="pmid">35306288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2022.114272</pub-id><pub-id pub-id-type="pmcid">PMC9007901</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pojani</surname><given-names>E</given-names></name><name name-style="western"><surname>Barlocco</surname><given-names>D</given-names></name></person-group><article-title>Selective inhibitors of histone deacetylase 10 (HDAC-10)</article-title><source>Curr. Med. Chem.</source><year>2022</year><volume>29</volume><fpage>2306</fpage><pub-id pub-id-type="doi">10.2174/0929867328666210901144658</pub-id><pub-id pub-id-type="pmid">34468295</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Pojani, E. &amp; Barlocco, D. Selective inhibitors of histone deacetylase 10 (HDAC-10). <italic toggle="yes">Curr. Med. Chem.</italic><bold>29</bold>, 2306. DOI:10.2174/0929867328666210901144658 (2022).<pub-id pub-id-type="pmid">34468295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929867328666210901144658</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Ptacek, J. et al. Selectivity of hydroxamate-and difluoromethyloxadiazole-based inhibitors of histone deacetylase 6 in vitro and in cells. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>24</bold>. 10.3390/ijms24054720 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24054720</pub-id><pub-id pub-id-type="pmcid">PMC10003107</pub-id><pub-id pub-id-type="pmid">36902164</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogl</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma</article-title><source>Clin. Cancer Re</source><year>2017</year><volume>23</volume><fpage>3307</fpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-2526</pub-id><pub-id pub-id-type="pmcid">PMC5496796</pub-id><pub-id pub-id-type="pmid">28053023</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Vogl, D. T. et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. <italic toggle="yes">Clin. Cancer Res.</italic><bold>23</bold>, 3307. 10.1158/1078-0432.CCR-16-2526 (2017).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-16-2526</pub-id><pub-id pub-id-type="pmcid">PMC5496796</pub-id><pub-id pub-id-type="pmid">28053023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><etal/></person-group><article-title>Histone deacetylase 6 in cancer</article-title><source>J. Hematol. Oncol.</source><year>2018</year><volume>11</volume><fpage>111</fpage><pub-id pub-id-type="doi">10.1186/s13045-018-0654-9</pub-id><pub-id pub-id-type="pmid">30176876</pub-id><pub-id pub-id-type="pmcid">PMC6122547</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Li, T. et al. Histone deacetylase 6 in cancer. <italic toggle="yes">J. Hematol. Oncol.</italic><bold>11</bold>, 111. 10.1186/s13045-018-0654-9 (2018).<pub-id pub-id-type="pmid">30176876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-018-0654-9</pub-id><pub-id pub-id-type="pmcid">PMC6122547</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osko</surname><given-names>JD</given-names></name><name name-style="western"><surname>Christianson</surname><given-names>DW</given-names></name></person-group><article-title>Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2020</year><volume>30</volume><fpage>127023</fpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2020.127023</pub-id><pub-id pub-id-type="pmid">32067866</pub-id><pub-id pub-id-type="pmcid">PMC7067655</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Osko, J. D. &amp; Christianson, D. W. Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6. <italic toggle="yes">Bioorg. Med. Chem. Lett.</italic><bold>30</bold>, 127023. 10.1016/j.bmcl.2020.127023 (2020).<pub-id pub-id-type="pmid">32067866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmcl.2020.127023</pub-id><pub-id pub-id-type="pmcid">PMC7067655</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbst-Gervasoni</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Christianson</surname><given-names>DW</given-names></name></person-group><article-title>Understanding RNA binding by the nonclassical zinc finger protein CPSF30, a key factor in polyadenylation during pre-mRNA processing</article-title><source>Biochemistry</source><year>2021</year><volume>60</volume><fpage>303</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.0c00940</pub-id><pub-id pub-id-type="pmid">33615774</pub-id><pub-id pub-id-type="pmcid">PMC8575367</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Herbst-Gervasoni, C. J. &amp; Christianson, D. W. Understanding RNA binding by the nonclassical zinc finger protein CPSF30, a key factor in polyadenylation during pre-mRNA processing. <italic toggle="yes">Biochemistry</italic><bold>60</bold>, 303&#8211;313. 10.1021/acs.biochem.0c00940 (2021).<pub-id pub-id-type="pmid">33615774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.biochem.0c00940</pub-id><pub-id pub-id-type="pmcid">PMC8575367</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>DD</given-names></name></person-group><article-title>Synthesis and some reactions of the N-Tosyl derivative of indoles and 2, 3-dihydrocarbazol-4 (1H)-one</article-title><source>Aust J. Chem.</source><year>1973</year><volume>26</volume><fpage>2555</fpage><pub-id pub-id-type="doi">10.1071/CH9732555</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Evans, D. D. Synthesis and some reactions of the N-Tosyl derivative of indoles and 2, 3-dihydrocarbazol-4 (1H)-one. <italic toggle="yes">Aust J. Chem.</italic><bold>26</bold>, 2555. 10.1071/CH9732555 (1973).</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Structure and synthesis of murrapanine, a novel skeletal indole-naphthoquinone alkaloid and cytotoxic principal from Murraya paniculata var. omphalocarpa</article-title><source>Tetrahedron Lett.</source><year>1989</year><volume>30</volume><fpage>6649</fpage><pub-id pub-id-type="doi">10.1016/S0040-4039(00)70641-1</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Wu, T. S. et al. Structure and synthesis of murrapanine, a novel skeletal indole-naphthoquinone alkaloid and cytotoxic principal from Murraya paniculata var. omphalocarpa. <italic toggle="yes">Tetrahedron Lett.</italic><bold>30</bold>, 6649. 10.1016/S0040-4039(00)70641-1 (1989).</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YY</given-names></name></person-group><article-title>Antifungal agents. Part 5: Synthesis and antifungal activities of aminoguanidine derivatives of N-arylsulfonyl-3-acylindoles</article-title><source>Bioorg Med. Chem Lett.</source><year>2010</year><volume>20</volume><fpage>7274</fpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2010.10.084</pub-id><pub-id pub-id-type="pmid">21067926</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Xu, H. &amp; Wang, Y. Y. Antifungal agents. Part 5: Synthesis and antifungal activities of aminoguanidine derivatives of N-arylsulfonyl-3-acylindoles. <italic toggle="yes">Bioorg Med. Chem Lett.</italic><bold>20</bold>, 7274. 10.1016/j.bmcl.2010.10.084 (2010).<pub-id pub-id-type="pmid">21067926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmcl.2010.10.084</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mertes</surname><given-names>MP</given-names></name><name name-style="western"><surname>Lin</surname><given-names>AJ</given-names></name></person-group><article-title>Cofactor inhibitors of thymidylate synthetase. Piperidine and tetrahydroquinoline analogs of tetrahydrofolic acid</article-title><source>J. Med. Chem.</source><year>1970</year><volume>13</volume><fpage>276</fpage><pub-id pub-id-type="doi">10.1021/jm00296a026</pub-id><pub-id pub-id-type="pmid">5418501</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Mertes, M. P. &amp; Lin, A. J. Cofactor inhibitors of thymidylate synthetase. Piperidine and tetrahydroquinoline analogs of tetrahydrofolic acid. <italic toggle="yes">J. Med. Chem.</italic><bold>13</bold>, 276. 10.1021/jm00296a026 (1970).<pub-id pub-id-type="pmid">5418501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm00296a026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase that favorably modulates lipid mediator biosynthesis in inflammation</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>156</volume><fpage>815</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.07.031</pub-id><pub-id pub-id-type="pmid">30053720</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Cheung, S. Y. et al. Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase that favorably modulates lipid mediator biosynthesis in inflammation. <italic toggle="yes">Eur. J. Med. Chem.</italic><bold>156</bold>, 815. 10.1016/j.ejmech.2018.07.031 (2018).<pub-id pub-id-type="pmid">30053720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2018.07.031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaedcke</surname><given-names>F</given-names></name><name name-style="western"><surname>Knorr</surname><given-names>R</given-names></name><name name-style="western"><surname>Zymalkowski</surname><given-names>F</given-names></name></person-group><article-title>Strukturabh&#228;ngigkeit der antiplasmodischen Wirkung von 3&#8208;[N (4&#8242;&#8208;Amidosulfonyl)&#8208;phenyl]&#8208;aminomethyl&#8208;chinolin</article-title><source>Arch. Pharm.</source><year>1980</year><volume>313</volume><fpage>166</fpage><pub-id pub-id-type="doi">10.1002/ardp.19803130209</pub-id><pub-id pub-id-type="pmid">6989342</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Gaedcke, F., Knorr, R. &amp; Zymalkowski, F. Strukturabh&#228;ngigkeit der antiplasmodischen Wirkung von 3&#8208;[N (4&#8242;&#8208;Amidosulfonyl)&#8208;phenyl]&#8208;aminomethyl&#8208;chinolin. <italic toggle="yes">Arch. Pharm.</italic><bold>313</bold>, 166. 10.1002/ardp.19803130209 (1980).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ardp.19803130209</pub-id><pub-id pub-id-type="pmid">6989342</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heimburg</surname><given-names>T</given-names></name><etal/></person-group><article-title>Structure-based design and biological characterization of selective histone deacetylase 8 (HDAC8) inhibitors with anti-neuroblastoma activity</article-title><source>J. Med. Chem.</source><year>2017</year><volume>60</volume><fpage>10188</fpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b01447</pub-id><pub-id pub-id-type="pmid">29190092</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Heimburg, T. et al. Structure-based design and biological characterization of selective histone deacetylase 8 (HDAC8) inhibitors with anti-neuroblastoma activity. <italic toggle="yes">J. Med. Chem.</italic><bold>60</bold>, 10188. 10.1021/acs.jmedchem.7b01447 (2017).<pub-id pub-id-type="pmid">29190092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.7b01447</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zessin</surname><given-names>M</given-names></name><etal/></person-group><article-title>One-atom substitution enables direct and continuous monitoring of histone deacylase activity</article-title><source>Biochemistry</source><year>2019</year><volume>58</volume><fpage>4777</fpage><pub-id pub-id-type="doi">10.1021/acs.biochem.9b00786</pub-id><pub-id pub-id-type="pmid">31682411</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Zessin, M. et al. One-atom substitution enables direct and continuous monitoring of histone deacylase activity. <italic toggle="yes">Biochemistry</italic><bold>58</bold>, 4777. 10.1021/acs.biochem.9b00786 (2019).<pub-id pub-id-type="pmid">31682411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.biochem.9b00786</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>P</given-names></name><etal/></person-group><article-title>Development of alkylated hydrazides as highly potent and selective class I histone deacetylase inhibitors with T cell modulatory properties</article-title><source>J. Med. Chem.</source><year>2022</year><volume>65</volume><fpage>16313</fpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01132</pub-id><pub-id pub-id-type="pmid">36449385</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Sun, P. et al. Development of alkylated hydrazides as highly potent and selective class I histone deacetylase inhibitors with T cell modulatory properties. <italic toggle="yes">J. Med. Chem.</italic><bold>65</bold>, 16313. 10.1021/acs.jmedchem.2c01132 (2022).<pub-id pub-id-type="pmid">36449385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.2c01132</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Synthesis, molecular docking and biological characterization of pyrazine linked 2-aminobenzamides as new class I selective histone deacetylase (HDAC) inhibitors with anti-leukemic activity</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>23</volume><fpage>369</fpage><pub-id pub-id-type="doi">10.3390/ijms23010369</pub-id><pub-id pub-id-type="pmid">35008795</pub-id><pub-id pub-id-type="pmcid">PMC8745332</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Ibrahim, H. S. et al. Synthesis, molecular docking and biological characterization of pyrazine linked 2-aminobenzamides as new class I selective histone deacetylase (HDAC) inhibitors with anti-leukemic activity. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>23</bold>, 369. 10.3390/ijms23010369 (2021).<pub-id pub-id-type="pmid">35008795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23010369</pub-id><pub-id pub-id-type="pmcid">PMC8745332</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berman</surname><given-names>HM</given-names></name><etal/></person-group><article-title>The protein data bank</article-title><source>Nucleic Acids Res.</source><year>2000</year><volume>28</volume><fpage>235</fpage><pub-id pub-id-type="doi">10.1093/nar/28.1.235</pub-id><pub-id pub-id-type="pmid">10592235</pub-id><pub-id pub-id-type="pmcid">PMC102472</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Berman, H. M. et al. The protein data bank. <italic toggle="yes">Nucleic Acids Res.</italic><bold>28</bold>, 235. 10.1093/nar/28.1.235 (2000).<pub-id pub-id-type="pmid">10592235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/28.1.235</pub-id><pub-id pub-id-type="pmcid">PMC102472</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Simoben, C. V. et al. Binding Free Energy (BFE) calculations and Quantitative Structure&#8211;Activity Relationship (QSAR) analysis of Schistosoma mansoni histone deacetylase 8 (sm HDAC8) inhibitors. <italic toggle="yes">Molecules</italic><bold>26</bold>. 10.3390/molecules26092584 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules26092584</pub-id><pub-id pub-id-type="pmcid">PMC8125515</pub-id><pub-id pub-id-type="pmid">33925246</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banks</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Integrated modeling program, applied chemical theory (IMPACT)</article-title><source>J. Comput. Chem.</source><year>2005</year><volume>26</volume><fpage>1752</fpage><pub-id pub-id-type="doi">10.1002/jcc.20292</pub-id><pub-id pub-id-type="pmid">16211539</pub-id><pub-id pub-id-type="pmcid">PMC2742605</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Banks, J. L. et al. Integrated modeling program, applied chemical theory (IMPACT). <italic toggle="yes">J. Comput. Chem.</italic><bold>26</bold>, 1752. 10.1002/jcc.20292 (2005).<pub-id pub-id-type="pmid">16211539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcc.20292</pub-id><pub-id pub-id-type="pmcid">PMC2742605</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Kollman</surname><given-names>PA</given-names></name><name name-style="western"><surname>Case</surname><given-names>DA</given-names></name></person-group><article-title>Automatic atom type and bond type perception in molecular mechanical calculations</article-title><source>J. Mol. Graph Model.</source><year>2006</year><volume>25</volume><fpage>247</fpage><pub-id pub-id-type="doi">10.1016/j.jmgm.2005.12.005</pub-id><pub-id pub-id-type="pmid">16458552</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Wang, J., Wang, W., Kollman, P. A. &amp; Case, D. A. Automatic atom type and bond type perception in molecular mechanical calculations. <italic toggle="yes">J. Mol. Graph Model.</italic><bold>25</bold>, 247. 10.1016/j.jmgm.2005.12.005 (2006).<pub-id pub-id-type="pmid">16458552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmgm.2005.12.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakalian</surname><given-names>A</given-names></name><name name-style="western"><surname>Jack</surname><given-names>DB</given-names></name><name name-style="western"><surname>Bayly</surname><given-names>CI</given-names></name></person-group><article-title>Fast, efficient generation of high&#8208;quality atomic charges. AM1&#8208;BCC model: II. Parameterization and validation</article-title><source>J. Comput. Chem.</source><year>2002</year><volume>23</volume><fpage>1623</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1002/jcc.10128</pub-id><pub-id pub-id-type="pmid">12395429</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Jakalian, A., Jack, D. B. &amp; Bayly, C. I. Fast, efficient generation of high&#8208;quality atomic charges. AM1&#8208;BCC model: II. Parameterization and validation. <italic toggle="yes">J. Comput. Chem.</italic><bold>23</bold>, 1623&#8211;1641. 10.1002/jcc.10128 (2002).<pub-id pub-id-type="pmid">12395429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcc.10128</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Jakalian, A., Bush, B. L., Jack, D. B. &amp; Bayly, C. I. Fast, efficient generation of high&#8208;quality atomic charges. AM1&#8208;BCC model: I. Method. <italic toggle="yes">J. Comput. Chem.</italic><bold>21</bold>, 132. 10.1002/jcc.10128 (2000).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcc.10128</pub-id><pub-id pub-id-type="pmid">12395429</pub-id></mixed-citation></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Man</surname><given-names>VH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Lee</surname><given-names>TS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>A fast and high-quality charge model for the next generation general AMBER force field</article-title><source>J. Chem. Phys.</source><year>2020</year><volume>153</volume><fpage>114502</fpage><pub-id pub-id-type="doi">10.1063/5.0019056</pub-id><pub-id pub-id-type="pmid">32962378</pub-id><pub-id pub-id-type="pmcid">PMC7728379</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">He, X., Man, V. H., Yang, W., Lee, T. S. &amp; Wang, J. A fast and high-quality charge model for the next generation general AMBER force field. <italic toggle="yes">J. Chem. Phys.</italic><bold>153</bold>, 114502. 10.1063/5.0019056 (2020).<pub-id pub-id-type="pmid">32962378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1063/5.0019056</pub-id><pub-id pub-id-type="pmcid">PMC7728379</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maier</surname><given-names>JA</given-names></name><etal/></person-group><article-title>ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB</article-title><source>J. Chem. Theory Comput.</source><year>2015</year><volume>11</volume><fpage>3696</fpage><pub-id pub-id-type="doi">10.1021/acs.jctc.5b00255</pub-id><pub-id pub-id-type="pmid">26574453</pub-id><pub-id pub-id-type="pmcid">PMC4821407</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Maier, J. A. et al. ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. <italic toggle="yes">J. Chem. Theory Comput.</italic><bold>11</bold>, 3696. 10.1021/acs.jctc.5b00255 (2015).<pub-id pub-id-type="pmid">26574453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jctc.5b00255</pub-id><pub-id pub-id-type="pmcid">PMC4821407</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Song</surname><given-names>LF</given-names></name><name name-style="western"><surname>Merz</surname><given-names>KM</given-names><suffix>Jr.</suffix></name></person-group><article-title>Parameterization of highly charged metal ions using the 12-6-4 LJ-type nonbonded model in explicit water</article-title><source>J. Phys. Chem. B</source><year>2015</year><volume>119</volume><fpage>883</fpage><pub-id pub-id-type="doi">10.1021/jp505875v</pub-id><pub-id pub-id-type="pmid">25145273</pub-id><pub-id pub-id-type="pmcid">PMC4306492</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Li, P., Song, L. F. &amp; Merz, K. M. Jr. Parameterization of highly charged metal ions using the 12-6-4 LJ-type nonbonded model in explicit water. <italic toggle="yes">J. Phys. Chem. B</italic><bold>119</bold>, 883. 10.1021/jp505875v (2015).<pub-id pub-id-type="pmid">25145273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jp505875v</pub-id><pub-id pub-id-type="pmcid">PMC4306492</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toukmaji</surname><given-names>C</given-names></name><name name-style="western"><surname>Sagui</surname><given-names>J</given-names></name><name name-style="western"><surname>Board</surname><given-names>T</given-names></name><name name-style="western"><surname>Darden</surname></name></person-group><article-title>Efficient particle-mesh Ewald based approach to fixed and induced dipolar interactions</article-title><source>J. Chem. Phys.</source><year>2000</year><volume>113</volume><fpage>10913</fpage><lpage>10927</lpage><pub-id pub-id-type="doi">10.1063/1.1324708</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Toukmaji, C., Sagui, J., Board, T. &amp; Darden Efficient particle-mesh Ewald based approach to fixed and induced dipolar interactions. <italic toggle="yes">J. Chem. Phys.</italic><bold>113</bold>, 10913&#8211;10927. 10.1063/1.1324708 (2000).</mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>